<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Cannabis‐based medicines and medical cannabis for adults with cancer pain - Häuser, W - 2023 | Cochrane Library</title> <meta content="Cannabis‐based medicines and medical cannabis for adults with cancer pain - Häuser, W - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014915.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Cannabis‐based medicines and medical cannabis for adults with cancer pain - Häuser, W - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014915.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD014915.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Cannabis‐based medicines and medical cannabis for adults with cancer pain" name="citation_title"/> <meta content="Winfried Häuser" name="citation_author"/> <meta content="Technische Universität München" name="citation_author_institution"/> <meta content="w.haeuser@web.de" name="citation_author_email"/> <meta content="Patrick Welsch" name="citation_author"/> <meta content="Health Care Center for Pain Medicine and Mental Health" name="citation_author_institution"/> <meta content="Lukas Radbruch" name="citation_author"/> <meta content="University Hospital of Bonn" name="citation_author_institution"/> <meta content="Emma Fisher" name="citation_author"/> <meta content="Rae Frances Bell" name="citation_author"/> <meta content="Haukeland University Hospital" name="citation_author_institution"/> <meta content="R Andrew Moore" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD014915.pub2" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/06/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014915.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014915.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014915.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Analgesics, Opioid [adverse effects]; *Cancer Pain [drug therapy]; *Cannabis; *Carcinoma, Non-Small-Cell Lung [drug therapy]; Codeine; *Lung Neoplasms [drug therapy]; *Medical Marijuana [adverse effects]; Morphine; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014915.pub2&amp;doi=10.1002/14651858.CD014915.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014915.pub2&amp;doi=10.1002/14651858.CD014915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014915.pub2&amp;doi=10.1002/14651858.CD014915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014915.pub2&amp;doi=10.1002/14651858.CD014915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014915.pub2&amp;doi=10.1002/14651858.CD014915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014915.pub2&amp;doi=10.1002/14651858.CD014915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014915.pub2&amp;doi=10.1002/14651858.CD014915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014915.pub2&amp;doi=10.1002/14651858.CD014915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014915.pub2&amp;doi=10.1002/14651858.CD014915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014915.pub2&amp;doi=10.1002/14651858.CD014915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014915.pub2&amp;doi=10.1002/14651858.CD014915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014915.pub2&amp;doi=10.1002/14651858.CD014915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014915.pub2&amp;doi=10.1002/14651858.CD014915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014915.pub2&amp;doi=10.1002/14651858.CD014915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014915.pub2&amp;doi=10.1002/14651858.CD014915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014915.pub2&amp;doi=10.1002/14651858.CD014915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014915.pub2&amp;doi=10.1002/14651858.CD014915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014915.pub2&amp;doi=10.1002/14651858.CD014915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014915.pub2&amp;doi=10.1002/14651858.CD014915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014915.pub2&amp;doi=10.1002/14651858.CD014915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014915.pub2&amp;doi=10.1002/14651858.CD014915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014915.pub2&amp;doi=10.1002/14651858.CD014915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD014915.pub2&amp;doi=10.1002/14651858.CD014915.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6zFwvAqw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD014915\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD014915\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014915\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014915\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","de","zh_HANT","th","pt","ms","ja","fa","id","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD014915.pub2",title:"Cannabis\\u2010based medicines and medical cannabis for adults with cancer pain",firstPublishedDate:"Jun 5, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014915.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014915.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD014915.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD014915.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014915.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD014915.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD014915.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD014915.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD014915.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD014915.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>15458 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD014915.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/full#CD014915-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/full#CD014915-sec-0215"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/full#CD014915-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/full#CD014915-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/full#CD014915-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/full#CD014915-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/full#CD014915-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/full#CD014915-sec-0209"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/appendices#CD014915-sec-0221"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/supinfo/CD014915-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/supinfo/CD014915-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Cannabis‐based medicines and medical cannabis for adults with cancer pain</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/information#CD014915-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Winfried Häuser</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/information#CD014915-cr-0005">Patrick Welsch</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/information#CD014915-cr-0006">Lukas Radbruch</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/information#CD014915-cr-0007">Emma Fisher</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/information#CD014915-cr-0008">Rae Frances Bell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD014915.pub2/information#CD014915-cr-0009">R Andrew Moore</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/information/en#CD014915-sec-0226">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 June 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD014915.pub2">https://doi.org/10.1002/14651858.CD014915.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD014915-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014915-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD014915-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014915-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014915-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD014915-abs-0009">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD014915-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD014915-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD014915-abs-0001" lang="en"> <section id="CD014915-sec-0001"> <h3 class="title" id="CD014915-sec-0001">Background</h3> <p>Pain is a common symptom in people with cancer; 30% to 50% of people with cancer will experience moderate‐to‐severe pain. This can have a major negative impact on their quality of life. Opioid (morphine‐like) medications are commonly used to treat moderate or severe cancer pain, and are recommended for this purpose in the World Health Organization (WHO) pain treatment ladder. Pain is not sufficiently relieved by opioid medications in 10% to 15% of people with cancer. In people with insufficient relief of cancer pain, new analgesics are needed to effectively and safely supplement or replace opioids. </p> </section> <section id="CD014915-sec-0002"> <h3 class="title" id="CD014915-sec-0002">Objectives</h3> <p>To evaluate the benefits and harms of cannabis‐based medicines, including medical cannabis, for treating pain and other symptoms in adults with cancer compared to placebo or any other established analgesic for cancer pain. </p> </section> <section id="CD014915-sec-0003"> <h3 class="title" id="CD014915-sec-0003">Search methods</h3> <p>We used standard, extensive Cochrane search methods. The latest search date was 26 January 2023. </p> </section> <section id="CD014915-sec-0004"> <h3 class="title" id="CD014915-sec-0004">Selection criteria</h3> <p>We selected double‐blind randomised, controlled trials (RCT) of medical cannabis, plant‐derived and synthetic cannabis‐based medicines against placebo or any other active treatment for cancer pain in adults, with any treatment duration and at least 10 participants per treatment arm. </p> </section> <section id="CD014915-sec-0005"> <h3 class="title" id="CD014915-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods. The primary outcomes were 1. proportions of participants reporting no worse than mild pain; 2. Patient Global Impression of Change (PGIC) of much improved or very much improved and 3. withdrawals due to adverse events. Secondary outcomes were 4. number of participants who reported pain relief of 30% or greater and overall opioid use reduced or stable; 5. number of participants who reported pain relief of 30% or greater, or 50% or greater; 6. pain intensity; 7. sleep problems; 8. depression and anxiety; 9. daily maintenance and breakthrough opioid dosage; 10. dropouts due to lack of efficacy; 11. all central nervous system adverse events. We used GRADE to assess certainty of evidence for each outcome. </p> </section> <section id="CD014915-sec-0006"> <h3 class="title" id="CD014915-sec-0006">Main results</h3> <p>We identified 14 studies involving 1823 participants. No study assessed the proportions of participants reporting no worse than mild pain on treatment by 14 days after start of treatment. </p> <p>We found five RCTs assessing oromucosal nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) or THC alone involving 1539 participants with moderate or severe pain despite opioid therapy. The double‐blind periods of the RCTs ranged between two and five weeks. Four studies with a parallel design and 1333 participants were available for meta‐analysis. </p> <p>There was moderate‐certainty evidence that there was no clinically relevant benefit for proportions of PGIC much or very much improved (risk difference (RD) 0.06, 95% confidence interval (CI) 0.01 to 0.12; number needed to treat for an additional beneficial outcome (NNTB) 16, 95% CI 8 to 100). There was moderate‐certainty evidence for no clinically relevant difference in the proportion of withdrawals due to adverse events (RD 0.04, 95% CI 0 to 0.08; number needed to treat for an additional harmful outcome (NNTH) 25, 95% CI 16 to endless). There was moderate‐certainty evidence for no difference between nabiximols or THC and placebo in the frequency of serious adverse events (RD 0.02, 95% CI −0.03 to 0.07). There was moderate‐certainty evidence that nabiximols and THC used as add‐on treatment for opioid‐refractory cancer pain did not differ from placebo in reducing mean pain intensity (standardised mean difference (SMD) −0.19, 95% CI −0.40 to 0.02). </p> <p>There was low‐certainty evidence that a synthetic THC analogue (nabilone) delivered over eight weeks was not superior to placebo in reducing pain associated with chemotherapy or radiochemotherapy in people with head and neck cancer and non‐small cell lung cancer (2 studies, 89 participants, qualitative analysis). Analyses of tolerability and safety were not possible for these studies. </p> <p>There was low‐certainty evidence that synthetic THC analogues were superior to placebo (SMD −0.98, 95% CI −1.36 to −0.60), but not superior to low‐dose codeine (SMD 0.03, 95% CI −0.25 to 0.32; 5 single‐dose trials; 126 participants) in reducing moderate‐to‐severe cancer pain after cessation of previous analgesic treatment for three to four and a half hours (2 single‐dose trials; 66 participants). Analyses of tolerability and safety were not possible for these studies. </p> <p>There was low‐certainty evidence that CBD oil did not add value to specialist palliative care alone in the reduction of pain intensity in people with advanced cancer. There was no difference in the number of dropouts due to adverse events and serious adverse events (1 study, 144 participants, qualitative analysis). </p> <p>We found no studies using herbal cannabis.</p> </section> <section id="CD014915-sec-0007"> <h3 class="title" id="CD014915-sec-0007">Authors' conclusions</h3> <p>There is moderate‐certainty evidence that oromucosal nabiximols and THC are ineffective in relieving moderate‐to‐severe opioid‐refractory cancer pain. There is low‐certainty evidence that nabilone is ineffective in reducing pain associated with (radio‐) chemotherapy in people with head and neck cancer and non‐small cell lung cancer. There is low‐certainty evidence that a single dose of synthetic THC analogues is not superior to a single low‐dose morphine equivalent in reducing moderate‐to‐severe cancer pain. There is low‐certainty evidence that CBD does not add value to specialist palliative care alone in the reduction of pain in people with advanced cancer. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD014915-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD014915-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD014915-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD014915-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD014915-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD014915-abs-0017">Français</a> </li> <li class="section-language"> <a class="" href="full/id#CD014915-abs-0015">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ja#CD014915-abs-0012">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD014915-abs-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD014915-abs-0010">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD014915-abs-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD014915-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD014915-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD014915-abs-0002" lang="en"> <h3>Cannabis‐based medicines for cancer pain</h3> <p><b>Do medicines based on cannabis help adults with cancer pain?</b> </p> <p><b>Key messages</b> </p> <p>Cannabis‐based medicines (CbMs) did not relieve cancer pain that did not respond to morphine‐like medicines. </p> <p>The studies analysed did not allow any statement to be made on the place of these medications in the World Health Organization (WHO) analgesic ladder for cancer pain. </p> <p>Trials with CbMs in cancer need to be very much better designed than those conducted so far. </p> <p><b>Pain in cancer and its treatment</b> </p> <p>One person in two or three who gets cancer will have pain that becomes moderate or severe in intensity. The pain tends to get worse as the cancer progresses. </p> <p>The WHO recommends taking morphine‐like medicines for moderate‐to‐severe pain from cancer, but 1 in 6 to 10 people with cancer pain do not experience sufficient pain relief from morphine‐like medicines. Several products based on the cannabis plant have been suggested as treatment for cancer pain. These products include inhaled or orally ingested herbal cannabis, and various oils, sprays or tablets containing active cannabis ingredients obtained from the plant, or made synthetically. Some people with cancer pain have reported that CbMs are effective for them, and that is often highlighted in the media. </p> <p><b>What did we want to find out?</b> </p> <p>If CbMs relieved cancer pain in people living with cancer.</p> <p>If CbMs were associated with any unwanted or harmful effects.</p> <p><b>What did we do?</b> </p> <p>We searched for clinical trials that examined CbMs compared to other medications to treat cancer pain in adults. </p> <p>We summarised the results of the studies and rated our confidence in the evidence, based on factors such as the methods and size of studies. </p> <p><b>What did we find?</b> </p> <p>We found 14 studies involving 1823 people. The biggest study included 399 people and the smallest study included 10 people. </p> <p>Studies were conducted in countries around the world; most (six) were based in North America. </p> <p>Five studies used one dose of CbM and lasted less than one day. Other studies lasted between two and eight weeks. </p> <p>Pharmaceutical companies funded seven studies.</p> <p>Six studies compared a mouth spray with a plant‐derived combination of tetrahydrocannabinol (THC), the principal psychoactive constituent of cannabis, and cannabidiol (CBD), an anti‐inflammatory ingredient of cannabis, against a fake medication (placebo). Seven studies compared an artificial cannabinoid mimicking the effects of THC against placebo. Of these seven studies, two studies compared against a morphine‐like medication (codeine), too. One study compared CBD against placebo. </p> <p>We did not find studies with herbal cannabis.</p> <p><b>Main results</b> </p> <p>Mouth spray with a plant‐derived combination of THC and CBD was probably not better than placebo in reducing pain in people with moderate‐to‐severe cancer pain despite opioid treatment. Thirty‐two out of 100 people reported to be much or very much improved by cannabis‐based mouth spray and 23 out of 100 people with mouth spray with placebo. A total of 19 out of 100 people withdrew early because of side effects by cannabis‐based mouth spray and 16 out of 100 people by mouth spray with placebo. There was no difference in serious side effects between the cannabis‐based mouth spray and a placebo mouth spray. </p> <p>Artificial cannabinoid mimicking the effects of THC may not be better than a fake medication in reducing pain associated with chemotherapy or radiochemotherapy in people with head and neck cancer and a certain type of lung cancer. </p> <p>A single dose of an artificial cannabinoid mimicking the effects of THC may be better than a single dose of placebo, but may not differ from a single small dose of a morphine‐like medication in reducing moderate‐to‐severe cancer pain after cessation of previous analgesic treatment for three to four and a half hours. </p> <p>CBD may not add value to specialist palliative care alone in the reduction of pain in people with advanced cancer. </p> <p>We found no studies with medical cannabis.</p> <p><b>What are the limitations of the evidence?</b> </p> <p>We are moderately confident in the evidence that a mouth spray with a plant‐derived combination of THC and CBD does not reduce severe cancer pain despite opioid treatment because studies did not provide information about everything that we could have used. </p> <p>We have little confidence in the evidence that an artificial cannabinoid mimicking the effects of THC (nabilone) does not reduce pain associated with chemotherapy or radiochemotherapy because the studies did not provide data about everything that we could have used, and because the studies were small. </p> <p>We have little confidence in the evidence that artificial cannabinoids mimicking the effects of THC reduce cancer pain after the previous pain‐relieving medication was stopped some hours before because the studies did not provide data about everything that we could have used, and because the studies were small. </p> <p>We have little confidence in the evidence that CBD added to standard palliative care does not reduce cancer pain because there was only one study available. </p> <p><b>How up to date is the evidence?</b> </p> <p>The evidence is up to date to January 2023.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD014915-sec-0215" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD014915-sec-0215"></div> <h3 class="title" id="CD014915-sec-0216">Implications for practice</h3> <section id="CD014915-sec-0216"> <p>The potential importance of cannabis‐based medicines (CbMs) and medical cannabis in the management of the different types and stages of cancer pain cannot be defined by our review because of the lack of any good evidence of efficacy or harm. The studies analysed do not allow any statement to be made on the place of these medications in the World Health Organization (WHO) analgesic ladder for cancer pain (e.g. if they can be used first, second or third line or as an adjunct). We do not know if the efficacy of single‐dose synthetic tetrahydrocannabinol (THC) analogue in analgesic‐naive people can be maintained. In addition, synthetic THC analogue was not superior to codeine 50 mg to 120 mg which corresponds to 7 mg, 5 mg and 18 mg morphine equivalent (<a href="./references#CD014915-bbs2-0059" title="Oregon Health Authority. Opioid calculator. www.oregonpainguidance.org/opioidmedcalculator/ (accessed prior to 3 May 2023).">Oregon Health Authority 2022</a>). There was moderate‐certainty evidence against the use of oromucosal nabiximols for cancer pain that is not sufficiently relieved by strong opioids and low‐certainty evidence against the use of nabilone to improve health‐related quality of life in people undergoing (radio‐)chemotherapy. In consideration of adverse effects, CbMs are not as well tolerated as is often claimed by some authors. Nervous system and psychiatric adverse events are prevalent and may limit the clinical usefulness of CbMs. </p> <p>Of note, we did not find a randomised controlled trial that could confirm the positive effects of medical cannabis on multiple symptoms of people with cancer (pain, sleep problems, psychological distress) described by Israeli observational studies (<a href="./references#CD014915-bbs2-0024" title="AviramJ , LewitusGM , VysotskiY , UribayevA , ProcacciaS , CohenI , et al. Short-term medical cannabis treatment regimens produced beneficial effects among palliative cancer patients. Pharmaceuticals (Basel)2020;13:435. [DOI: 10.3390/ph13120435]">Aviram 2020</a>; <a href="./references#CD014915-bbs2-0025" title="Bar-Lev SchleiderL , MechoulamR , LedermanV , HilouM , LencovskyO , BetzalelO , et al. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. European Journal of Internal Medicine2018;49:37-43. [DOI: 10.1016/j.ejim.2018.01.023]">Bar‐Lev Schneider 2018</a>). We hope that the ongoing trials with THC and cannabidiol (CBD)‐rich medical cannabis will provide high‐certainty evidence of medical cannabis in the treatment of cancer pain, as currently the certainty is low (<a href="./references#CD014915-bbs2-0016" title="ACTRN12619001534178. A phase I/II double-blind, randomised controlled trial assessing effect of medicinal cannabis on quality of life and symptom control in advanced cancer. anzctr.org.au/ACTRN12619001534178.aspx (first received 30 September 2019). [anzctr.org.au/ACTRN12619001534178.aspx]">ACTRN12619001534178</a>; <a href="./references#CD014915-bbs2-0017" title="ACTRN12621001302842. NanaBis™ an oro-buccal administered delta9-tetrahydrocannabinol (d9-THC) and cannabidiol (CBD) medicine for the management of chronic pain from metastatic bone cancer. anzctr.org.au/ACTRN12621001302842.aspx (first received 14 April 2021). [anzctr.org.au/ACTRN12621001302842.aspx]">ACTRN12621001302842</a>; <a href="./references#CD014915-bbs2-0018" title="EudraCT 001382-32. A double-blind, randomized phase 1/2 study to assess the efficacy and safety of BCT-521 versus placebo for pain associated with cancer inpatients already receiving standard of care treatment with opioids. www.clinicaltrialsregister.eu/ctr-search/trial/2019-001382-32/PL/ (first received 1 August 2019). ">EudraCT 001382‐32</a>; <a href="./references#CD014915-bbs2-0019" title="HardyJ , HaywoodA , GognaG , MartinJ , YatesP , GreerR , et al. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Trials2020;21:611. [DOI: 10.1186/s13063-020-04541-6]">Hardy 2020</a>; <a href="./references#CD014915-bbs2-0020" title="NCT04042545. Safety and efficacy of inhaled cannabis for the uncontrolled pain relief in patients with advanced cancer (PLENITUDE). clinicaltrials.gov/ct2/show/NCT04042545 (first received 2 August 2019). [clinicaltrials.gov/ct2/show/NCT04042545]">NCT04042545</a>). Currently, the European Pain Federation recommends clinicians should consider the use of CbMs only on a case‐to‐case basis. Taking patient preferences into consideration, an individual therapeutic trial in opioid‐naive people with cancer can be considered. An individual therapeutic trial may also be considered in people with moderate‐to‐severe cancer pain despite optimised pharmacological therapy including co‐analgesics (<a href="./references#CD014915-bbs2-0045" title="HäuserW , FinnDP , KalsoE , Krcevski-SkvarcN , KressHG , MorlionB , et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. European Journal of Pain2018;22:1547-64. [DOI: 10.1002/ejp.1297]">Häuser 2018</a>). Smoking of herbal cannabis is not recommended for people with cancer‐related pain as there is no easily defined dosage of cannabis ingredients and smoking presents dangers for physical health. In the event that a person insists on the use of cannabis flowers used for medical reasons, it is prudent for the healthcare professional to recommend inhalation using a vaporiser and oral intake as cannabis oil extract (<a href="./references#CD014915-bbs2-0038" title="FitzcharlesMA , NiakiOZ , HauserW , HazlewoodG , Canadian Rheumatology Association. Position statement: a pragmatic approach for medical cannabis and patients with rheumatic diseases. Journal of Rheumatology2019;46:532-8. [DOI: 10.3899/jrheum.181120]">Fitzcharles 2019</a>). </p> </section> <h3 class="title" id="CD014915-sec-0217">Implications for research</h3> <section id="CD014915-sec-0217"> <p> <ul id="CD014915-list-0016"> <li> <p>Studies should clearly define if the medication aims to relieve pain arising as a direct consequence of the cancer or of cancer therapy, or both. </p> </li> <li> <p>Pain mechanisms underlying the cancer pain (e.g. nociceptive, neuropathic) should be reported to enable subgroup analyses of efficacy according to pain mechanisms. </p> </li> <li> <p>Placebo‐controlled studies without absence of any established analgesic for cancer pain are unlikely to be ethically feasible. WHO analgesic ladder‐recommended medication as comparator would allow the assessment of comparative efficacy and safety. </p> </li> <li> <p>Studies with different CbMs arms (e.g. THC‐rich, CBD‐rich, balanced THC/CBD ratio) are necessary to define the optimal ratio of THC and CBD for cancer pain. </p> </li> <li> <p>Many of the studies were very small, and, combined with cross‐over design and consequent attrition, resulted in reporting on very few participants. Much larger studies of at least several hundred participants are needed. </p> </li> <li> <p>Prospective cohort studies incorporating initial randomisation but a pragmatic design in order to provide immediately relevant information on effectiveness and costs should complement randomised controlled trials. </p> </li> <li> <p>It is preferable that study protocols define that treating people with CbMs who do not have pain relief is unacceptable, so that there would be built‐in stopping rules linked to pain relief after an adequate trial of therapy. </p> </li> <li> <p>Reporting the details of the assessment of adverse events (spontaneous reports, open questions, symptom questionnaires) is mandatory because the type and frequency of adverse events is influenced by the modes of assessment. </p> </li> <li> <p>Reporting of mean pain changes should be complemented using responder analyses (pain relief of 50% or greater or participants experiencing mild or no pain). </p> </li> <li> <p>Imputation method are to be abandoned, as the outcome desired is that of adequate pain relief in the longer term, and for that people have to continue on therapy. Withdrawal for any reason has to be classified as treatment failure. </p> </li> <li> <p>Study data have to be made available to review authors for individual participant data analyses. </p> </li> <li> <p>Systematic reviews should not pool experimental and clinical studies, or studies aimed to relieve pain arising as a direct consequence of the cancer with studies aimed to relieve cancer therapy‐related pain. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD014915-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD014915-sec-0008"></div> <div class="table" id="CD014915-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Cannabis‐based medicines compared with placebo medication for cancer pain</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cannabis‐based medicines compared with placebo medication for cancer pain</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with cancer pain </p> <p><b>Settings:</b> outpatient study centres and hospitals in Europe and North America </p> <p><b>Intervention:</b> oromucosal THC with or without CBD </p> <p><b>Comparison:</b> oromucosal placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Observed outcome (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Oromucosal placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Oromucosal THC with or without CBD</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants reporting no worse than mild pain by 14 days after start of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No data for this outcome were reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PGIC of much improved or very much improved</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>230 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>320 per 1000</b><br/>(95% CI 290 to 350 per 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RD 0.06</b> (0.01 to 0.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>996 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 16 (95% CI 8 to 100)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>190 per 1000</b><br/>(95% CI 170 to 210 per 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RD 0.04</b> </p> <p>(0.00 to 0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1332 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH 25</p> <p>(95% CI 12 to endless)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean pain intensity</b> (Numeric Rating Scale 0–10) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain intensity at baseline was 5.6 (SD 1.2)<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain intensity in the intervention group was <b>0.19 SDs lower</b> (0.40 lower to 0.02 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD −0.19</b> (−0.40 to 0.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1315 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Daily maintenance opioid dosage</b> (mg morphine equivalent) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean dosage at baseline was 159.7 (SD 121.2) mg/day<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean dosage in the intervention group was <b>0.08 SDs higher</b> (0.10 lower to 0.27 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD 0.08</b> (−0.10 to 0.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>970 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Daily breakthrough opioid dosage</b> (mg morphine equivalent) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean dosage at baseline was 26.4 (SD 40.4) mg/day<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean dosage in the intervention group was <b>0.08 SDs lower</b> (0.23 lower to 0.07 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD −0.08</b> (−0.23 to 0.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>957 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants experiencing any serious adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>210 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b><br/>(95% CI 220 to 260 per 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RD</b> </p> <p><b>0.02</b> (−0.03 to 0.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1330 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CBD:</b> cannabidiol; <b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>PGIC:</b> Patient Global Impression of Change; <b>RD:</b> risk difference; <b>SD:</b> standard deviation; <b>SMD:</b> standardised mean difference; <b>THC:</b> tetrahydrocannabinol. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level due to limitations of study.<br/><sup>b</sup><a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>.<br/><sup>c</sup> Downgraded two levels due to limitations of study design and imprecision of results. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD014915-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD014915-sec-0009"></div> <section id="CD014915-sec-0010"> <h3 class="title" id="CD014915-sec-0010">Description of the condition</h3> <p>Cancer is the second leading cause of death globally, accounting for an estimated 9.6 million deaths, or one in six deaths, in 2018 (<a href="./references#CD014915-bbs2-0072" title="World Health Organization. Cancer, 2021. Available from www.who.int/health-topics/cancer#tab=tab_1 (accessed 21 June 2021).">WHO 2021</a>). Lung, prostate, colorectal, stomach and liver cancer are the most common types of cancer in men, while breast, colorectal, lung, cervical and thyroid cancer are the most common amongst women (<a href="./references#CD014915-bbs2-0072" title="World Health Organization. Cancer, 2021. Available from www.who.int/health-topics/cancer#tab=tab_1 (accessed 21 June 2021).">WHO 2021</a>). Pain is one of the most feared symptoms associated with cancers, and can occur at any time during the course of the disease. The frequency and intensity of pain tend to increase as the cancer advances (<a href="./references#CD014915-bbs2-0068" title="vanden Beuken-van EverdingenMH , HochstenbachLM , JoostenEA , Tjan-HeijnenVC , JanssenDJ . Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. Journal of Pain and Symptom Management2016;51:1070-90. [DOI: 10.1016/j.jpainsymman.2015.12.340]">van den Beuken‐van Everdingen 2016</a>). One systematic review has shown that approximately 40% of people living with cancer experienced pain after curative treatment, 55% during cancer treatment, and 66% in advanced disease (<a href="./references#CD014915-bbs2-0068" title="vanden Beuken-van EverdingenMH , HochstenbachLM , JoostenEA , Tjan-HeijnenVC , JanssenDJ . Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. Journal of Pain and Symptom Management2016;51:1070-90. [DOI: 10.1016/j.jpainsymman.2015.12.340]">van den Beuken‐van Everdingen 2016</a>). Pain may be specifically related to the cancer (direct tumour effects, systemic tumour effects), the effects of cancer treatments (e.g. radiation or chemotherapy) or due to some other comorbid disease (<a href="./references#CD014915-bbs2-0067" title="SwarmRA , PaiceJA , AnghelescuDL , AreM , BruceJY , BugaS . Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network2019;17:977-1007. [DOI: 10.6004/jnccn.2019.0038]">Swarm 2019</a>). In this review, we defined cancer pain as pain arising as a direct consequence of the cancer or of cancer therapy (or both), and not due to another condition. </p> <p>The World Health Organization (WHO) analgesic ladder advocates a stepwise approach to analgesia for cancer pain. It recommends that opioids be used as first‐line treatment for moderate‐to‐severe cancer pain (<a href="./references#CD014915-bbs2-0071" title="World Health Organization. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents, 2019. Available from www.who.int/ncds/management/palliative-care/cancer-pain-guidelines/en (accessed 21 June 2021).">WHO 2019</a>). An overview of Cochrane Reviews found the quantity and quality of evidence supporting the use of opioids for cancer pain to be low (<a href="./references#CD014915-bbs2-0073" title="WiffenPJ , WeeB , DerryS , BellRF , MooreRA . Opioids for cancer pain – an overview of Cochrane Reviews. Cochrane Database of Systematic Reviews2017, Issue 7. Art. No: CD012592. [DOI: 10.1002/14651858.CD012592]">Wiffen 2017</a>). In clinical practice, most people with cancer will achieve adequate pain relief with opioids. However, wide interpatient variability in the response to opioids has been reported and 10% to 15% of people with cancer pain are defined as opioid non‐responders (<a href="./references#CD014915-bbs2-0031" title='CorliO , FlorianiI , RobertoA , MontanariM , GalliF , GrecoMT , et al. Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV "real life" trial on the variability of response to opioids. Annals of Oncology2016;27:1107-15. [DOI: 10.1093/annonc/mdw097]'>Corli 2016</a>). Therefore, there is a substantial need for new analgesics that can effectively and safely supplement or replace opioids in people with insufficient relief of cancer pain. </p> </section> <section id="CD014915-sec-0011"> <h3 class="title" id="CD014915-sec-0011">Description of the intervention</h3> <p>The cannabinoid (CB) system is ubiquitous in the animal kingdom and is said to perform multiple functions that move the organism back to equilibrium. A large body of evidence currently supports the presence of CB receptors and ligands in the peripheral and central nervous system, but also in other tissues such as bone and in the immune system (<a href="./references#CD014915-bbs2-0060" title="OwensB . Drug development: the treasure chest. Nature2015;525:S6-8. [DOI: 10.1038/525S6a]">Owens 2015</a>; <a href="./references#CD014915-bbs2-0065" title="SolimanN , HohmannAG , HaroutounianS , WeverK , RiceASC , FinnD . A protocol for the systematic review and meta-analysis of studies in which cannabinoids were tested for antinociceptive effects in animal models of pathological or injury-related persistent pain. Pain Reports2019;4:e766. [DOI: 10.1097/PR9.000000000000076]">Soliman 2019</a>). The endocannabinoid system is said to have three broad and overlapping functions in mammals. The first is a stress recovery role, operating in a feedback loop in which endocannabinoid signalling is activated by stress and functions to return endocrine, nervous and behavioural systems to homeostatic balance. The second is to control energy balance through regulation of the intake, storage and utilisation of food. The third involves immune regulation; endocannabinoid signalling is activated by tissue injury and modulates immune and inflammatory responses (<a href="./references#CD014915-bbs2-0044" title="HillardCJ , WeinlanderKM , StuhrKL . Contributions of endocannabinoid signalling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience2012;204:207-29. [DOI: 10.1016]">Hillard 2012</a>). Thus, the endocannabinoid neuromodulatory system is assumed to be involved in multiple physiological functions, such as antinociception, cognition and memory, endocrine function, nausea and vomiting, inflammation and immune recognition (<a href="./references#CD014915-bbs2-0032" title="De VriesM , vanRijckevorselDC , Wilder-SmithOH , vanGoorH . Dronabinol and chronic pain: importance of mechanistic considerations. Expert Opinion on Pharmacotherapy2014;15:1525-34. [DOI: 10.1517/14656566.2014.918102]">De Vries 2014</a>; <a href="./references#CD014915-bbs2-0044" title="HillardCJ , WeinlanderKM , StuhrKL . Contributions of endocannabinoid signalling to psychiatric disorders in humans: genetic and biochemical evidence. Neuroscience2012;204:207-29. [DOI: 10.1016]">Hillard 2012</a>). </p> <p><i>Cannabis</i> is a genus of the flowering plant in the family Cannabaceae. The number of species within the genus is disputed. Three species are recognised, <i>Cannabis sativa</i> , <i>Cannabis indica</i> and <i>Cannabis ruderalis</i>. These plants, commonly known as marijuana, have been used for pain relief for millennia, and have additional effects on appetite, sleep and mood (<a href="./references#CD014915-bbs2-0048" title="KalantH . Medicinal use of cannabis: history and current status. Pain Research &amp; Management2001;6:80-91. [DOI: 10.1155/2001/469629]">Kalant 2001</a>). Because of the multiple mechanisms of action of cannabis in the human organism, cannabis has the potential to modulate some of the most common and debilitating symptoms of cancer and its treatments, including nausea and vomiting, loss of appetite and pain (<a href="./references#CD014915-bbs2-0049" title="KlecknerAS , KlecknerIR , KamenCS , TejaniMA , JanelsinsMC , MorrowGR , et al. Opportunities for cannabis in supportive care in cancer. Therapeutic Advances in Medical Oncology2019;11:1758835919866362. [DOI: 10.1177/1758835919866362]">Kleckner 2019</a>). </p> </section> <section id="CD014915-sec-0012"> <h3 class="title" id="CD014915-sec-0012">How the intervention might work</h3> <p>Cannabis contains over 450 compounds, with at least 120 classified as phytocannabinoids. Two are of particular medical interest. Delta 9‐tetrahydrocannabinol (delta 9‐THC) is the main active constituent, with psychoactive (e.g. reduction of anxiety) and pain‐relieving properties. The second molecule of interest is cannabidiol (CBD), which has lower affinity for the CB receptors and the potential to counteract the negative effects of tetrahydrocannabinol (THC) on memory, mood and cognition, but may also have an effect on pain modulation due to anti‐inflammatory properties. The specific roles of currently identified cannabis‐based medicines (CbM) that act as ligands at CB receptors within the nervous system (primarily but not exclusively CB1 receptors) and in the periphery (primarily but not exclusively CB2 receptors) are only partially elucidated, but there are many preclinical data to support their influence on nociception (<a href="./references#CD014915-bbs2-0060" title="OwensB . Drug development: the treasure chest. Nature2015;525:S6-8. [DOI: 10.1038/525S6a]">Owens 2015</a>; <a href="./references#CD014915-bbs2-0065" title="SolimanN , HohmannAG , HaroutounianS , WeverK , RiceASC , FinnD . A protocol for the systematic review and meta-analysis of studies in which cannabinoids were tested for antinociceptive effects in animal models of pathological or injury-related persistent pain. Pain Reports2019;4:e766. [DOI: 10.1097/PR9.000000000000076]">Soliman 2019</a>). It is also hypothesised that cannabis reduces alterations in cognitive and autonomic processing in chronic pain states. The frontal‐limbic distribution of CB receptors in the brain suggests that cannabis may preferentially target the affective qualities of pain (<a href="./references#CD014915-bbs2-0051" title="LeeMC , PlonerM , WiechK , BingelU , WanigasekeraV , BrooksJ , et al. Amygdala activity contributes to the dissociative effect of cannabis on pain perception. Pain2013;134:123-34. [DOI: 10.1016/j.pain.2012.09.017]">Lee 2013</a>). </p> <p>Terminology and definitions of CbMs vary in the literature. A terminology based on the proposals of the task forces of the European Pain Federation (EFIC) (<a href="./references#CD014915-bbs2-0045" title="HäuserW , FinnDP , KalsoE , Krcevski-SkvarcN , KressHG , MorlionB , et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. European Journal of Pain2018;22:1547-64. [DOI: 10.1002/ejp.1297]">Häuser 2018</a>), and the International Association for the Study of Pain (IASP) (<a href="./references#CD014915-bbs2-0065" title="SolimanN , HohmannAG , HaroutounianS , WeverK , RiceASC , FinnD . A protocol for the systematic review and meta-analysis of studies in which cannabinoids were tested for antinociceptive effects in animal models of pathological or injury-related persistent pain. Pain Reports2019;4:e766. [DOI: 10.1097/PR9.000000000000076]">Soliman 2019</a>) is listed in <a href="./appendices#CD014915-sec-0222">Appendix 1</a>. </p> <p>CbMs are available in different forms.</p> <p>Licenced medical drugs or products currently being tested for medical use are as follows.</p> <p> <ul id="CD014915-list-0001"> <li> <p>Plant‐derived CBs: oromucosal THC and CBD (nabiximols; Sativex) or oral CBD (Epidiolex). Nabiximols is approved in some countries for the treatment of refractory spasticity in people with multiple sclerosis (<a href="./references#CD014915-bbs2-0050" title="Krcevski-SkvarcN , WellsC , HäuserW . Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: a survey of the status in the chapters of the European Pain Federation. European Journal of Pain2018;22:440-54. [DOI: 10.1002/ejp.1147]">Krcevski‐Skvarc 2018</a>). Oral CBD is approved by the European Medicines Agency for the management of Dravet syndrome and Lennox‐Gastaut syndrome, two rare forms of epilepsy in children (<a href="./references#CD014915-bbs2-0035" title="European Medicines Agency. Epydiolex (2019). Available from www.ema.europa.eu/en/medicines/human/EPAR/epidyolex (accessed 21 June 2021).">European Medicines Agency 2019</a>). </p> </li> <li> <p>Synthetic CBs: nabilone (Cesamet or Canemes), a synthetic THC, is approved in some countries for the management of refractory nausea/emesis in people with cancer (<a href="./references#CD014915-bbs2-0021" title="AbuhasiraR , ShbiroL , LandschaftY . Medical use of cannabis and cannabinoids containing products – regulations in Europe and North America. European Journal of Internal Medicine2018;49:2-6. [DOI: 10.1016/j.ejim.2018.01.001]">Abuhasira 2018</a>; <a href="./references#CD014915-bbs2-0050" title="Krcevski-SkvarcN , WellsC , HäuserW . Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: a survey of the status in the chapters of the European Pain Federation. European Journal of Pain2018;22:440-54. [DOI: 10.1002/ejp.1147]">Krcevski‐Skvarc 2018</a>). Dronabinol (Marinol or Syndros), a synthetic THC, is approved for similar therapeutic use in some countries (<a href="./references#CD014915-bbs2-0021" title="AbuhasiraR , ShbiroL , LandschaftY . Medical use of cannabis and cannabinoids containing products – regulations in Europe and North America. European Journal of Internal Medicine2018;49:2-6. [DOI: 10.1016/j.ejim.2018.01.001]">Abuhasira 2018</a>; <a href="./references#CD014915-bbs2-0050" title="Krcevski-SkvarcN , WellsC , HäuserW . Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: a survey of the status in the chapters of the European Pain Federation. European Journal of Pain2018;22:440-54. [DOI: 10.1002/ejp.1147]">Krcevski‐Skvarc 2018</a>). Levonantradol, a potent synthetic THC is used in research, but is not available as a licensed therapeutic drug in any country. </p> </li> </ul> </p> <p>Magistral preparations (i.e. any medicinal product prepared in a pharmacy in accordance with a medical prescription for an individual patient) of cannabis plant derivatives as follows. </p> <p> <ul id="CD014915-list-0002"> <li> <p>Defined CBs such as plant‐derived dronabinol (THC) or plant‐derived CBD</p> </li> <li> <p>Herbal cannabis, resins and extracts, such as oil or tinctures with defined content of THC or CBD (or both), together with other active ingredients (phytocannabinoids other than CBD/THC, such as terpenes and flavonoids) </p> </li> </ul> </p> <p>The main forms of administration are as follows.</p> <p> <ul id="CD014915-list-0003"> <li> <p>Oromucosal: spray (nabiximols)</p> </li> <li> <p>Oral: capsules (dronabinol, nabilone), oil (CBD), extracts (dronabinol, herbal cannabis)</p> </li> <li> <p>Smoke or vapour inhalation: CBD, dronabinol, herbal cannabis, resins</p> </li> <li> <p>Topical or rectal: CBD, herbal cannabis, resins, extracts</p> </li> </ul> </p> <p>There is a great variability in European countries with regard to the availability of the different CbMs and medical cannabis and their reimbursement by health statutory companies (<a href="./references#CD014915-bbs2-0050" title="Krcevski-SkvarcN , WellsC , HäuserW . Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: a survey of the status in the chapters of the European Pain Federation. European Journal of Pain2018;22:440-54. [DOI: 10.1002/ejp.1147]">Krcevski‐Skvarc 2018</a>). </p> <p>In addition, CBD and extracts of cannabis flowers (THC content less than 0.2%) are available in many countries as nutritional supplements (<a href="./references#CD014915-bbs2-0061" title="RadbruchL , HäuserW . Cannabidiol. Schmerz2020;34:115-6.">Radbruch 2020</a>). </p> <p>CB receptor antagonists and negative allosteric modulators (e.g. rimonabant (SR141716A)) and modulators that increase or enhance endocannabinoid system activity (e.g. fatty acid amide hydrolase inhibitors) are experimental medications which have been not yet been approved for use in pain therapy outside clinical studies (<a href="./references#CD014915-bbs2-0074" title="YeL , CaoZ , WangW , ZhouN . New insights in cannabinoid receptor structure and signaling. Current Molecular Pharmacology2019;12:239-48. [DOI: 10.2174/1874467212666190215112036]">Ye 2019</a>). </p> </section> <section id="CD014915-sec-0013"> <h3 class="title" id="CD014915-sec-0013">Why it is important to do this review</h3> <p>Contrary to the usual path of drug approval, CbMs in an increasing number of European countries have bypassed traditional approval by drug agencies and have been made available by legislative bodies as therapeutic products for pain management (<a href="./references#CD014915-bbs2-0050" title="Krcevski-SkvarcN , WellsC , HäuserW . Availability and approval of cannabis-based medicines for chronic pain management and palliative/supportive care in Europe: a survey of the status in the chapters of the European Pain Federation. European Journal of Pain2018;22:440-54. [DOI: 10.1002/ejp.1147]">Krcevski‐Skvarc 2018</a>). Propelled by public advocacy and the media, medical cannabis in particular has been promoted as an effective and safe treatment for cancer pain (<a href="./references#CD014915-bbs2-0027" title="BlakeA , WanBA , MalekL , DeAngelisC , DiazP , LaoN , et al. A selective review of medical cannabis in cancer pain management. Annals Palliative Medicine2017;6:S215-22. [DOI: 10.21037/apm.2017.08.05]">Blake 2017</a>). Other benefits that are quoted include the potential reduction of harm related to opioid use, and the purported benefits for sleep disturbance as well as mood disorders (<a href="./references#CD014915-bbs2-0069" title="VyasMB , LeBaronVT , GilsonAM . The use of cannabis in response to the opioid crisis: a review of the literature. Nursing Outlook2018;66:56-65. [DOI: 10.1016/j.outlook.2017.08.012]">Vyas 2018</a>). The worldwide surge in use of cannabis in the management of people with cancer is illustrated by the prevalent use of medical cannabis and illegal cannabis by up to 40% of people with cancer in Canada and Israel, countries where legal access to medical cannabis is available (<a href="./references#CD014915-bbs2-0025" title="Bar-Lev SchleiderL , MechoulamR , LedermanV , HilouM , LencovskyO , BetzalelO , et al. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. European Journal of Internal Medicine2018;49:37-43. [DOI: 10.1016/j.ejim.2018.01.023]">Bar‐Lev Schneider 2018</a>; <a href="./references#CD014915-bbs2-0052" title="MartellK , FairchildA , LeGerrierB , SinhaR , BakerS , LiuH , et al. Rates of cannabis use in patients with cancer. Current Oncology2018;25:219-25. [DOI: 10.3747/co.25.3983]">Martell 2018</a>). </p> <p>At the time of writing this review, the amount and quality of evidence for CbMs for chronic pain has been low, with the evidence compromised by studies of short duration and small numbers of participants (<a href="./references#CD014915-bbs2-0037" title="FisherE , MooreRA , FogartyAE , FinnDP , FinnerupNB , GilronI , et al. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain2021;162(Suppl 1):S45-66. [DOI: 10.1097/j.pain.0000000000001929]">Fisher 2021</a>; <a href="./references#CD014915-bbs2-0066" title="StockingsE , CampbellG , HallWD , NielsenS , ZagicD , RahmanR , et al. Cannabis and cannabinoids for the treatment of people with chronic non-cancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain2018;158:1932-54. [10.1097/j.pain.0000000000001293]">Stockings 2018</a>). In addition, a systematic overview of systematic reviews has pointed out that non‐Cochrane systematic reviews of CBs for pain are of overwhelmingly low or very low quality (<a href="./references#CD014915-bbs2-0058" title="MooreRA , FisherE , FinnDP , FinnerupNB , GilronI , HaroutounianS , et al. Cannabinoids, cannabis, and cannabis-based medicines for pain management: an overview of systematic reviews. Pain2021;62(Suppl 1):S67-79. [DOI: 10.1097/j.pain.0000000000001941]">Moore 2021</a>). A 2020 systematic review of randomised controlled trials (RCTs) of CbMs for chronic pain concluded that studies in this field have unclear or high risk of bias, and outcomes had GRADE ratings of low‐ or very low‐certainty evidence, with little confidence in the estimates of effect (<a href="./references#CD014915-bbs2-0037" title="FisherE , MooreRA , FogartyAE , FinnDP , FinnerupNB , GilronI , et al. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain2021;162(Suppl 1):S45-66. [DOI: 10.1097/j.pain.0000000000001929]">Fisher 2021</a>). The systematic review found no benefit of nabiximols compared to placebo, for at least 30% pain relief (two RCTs delivering treatment of two to five weeks) and mean change of pain from baseline (four RCTs delivering treatment of two to five weeks). Another systematic review analysed the same RCTs as <a href="./references#CD014915-bbs2-0037" title="FisherE , MooreRA , FogartyAE , FinnDP , FinnerupNB , GilronI , et al. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain2021;162(Suppl 1):S45-66. [DOI: 10.1097/j.pain.0000000000001929]">Fisher 2021</a> and found no benefit of nabiximols when compared to placebo for reducing pain and sleep problems (<a href="./references#CD014915-bbs2-0046" title="HäuserW , WelschP , KloseP , RadbruchL , FitzcharlesMA . Efficacy, tolerability and safety of cannabis-based medicines for cancer pain. A systematic review with meta-analysis of randomised controlled trials. Schmerz2019;33:424-36. [DOI: 10.1007/s00482-019-037]">Häuser 2019</a>). However, this review found patient impression of change to be much or very much improved in the group receiving nabiximols (<a href="./references#CD014915-bbs2-0046" title="HäuserW , WelschP , KloseP , RadbruchL , FitzcharlesMA . Efficacy, tolerability and safety of cannabis-based medicines for cancer pain. A systematic review with meta-analysis of randomised controlled trials. Schmerz2019;33:424-36. [DOI: 10.1007/s00482-019-037]">Häuser 2019</a>). </p> <p>Additional outcomes have gained importance to assess the efficacy and safety of CbMs for cancer pain. The US Food and Drug Administration (FDA) has suggested new combined responder outcomes for cancer pain trials: participants are only considered responders if they experience a clinically significant decrease in pain intensity compared with baseline at the primary analysis time point, and overall analgesic use is either decreased or stable compared with baseline (<a href="./references#CD014915-bbs2-0026" title="BaschE , TrentacostiAM , BurkeLB , KwitkowskiV , KaneRC , AutioKA , et al. Pain palliation measurement in cancer clinical trials: the US Food and Drug Administration perspective. Cancer2014;106:dju244. [DOI: 10.1093/jnci/dju244]">Basch 2014</a>). Moreover, Cochrane Reviews of the use of opioids for cancer pain have favoured the primary outcome of mild or no pain at 14 days (<a href="./references#CD014915-bbs2-0073" title="WiffenPJ , WeeB , DerryS , BellRF , MooreRA . Opioids for cancer pain – an overview of Cochrane Reviews. Cochrane Database of Systematic Reviews2017, Issue 7. Art. No: CD012592. [DOI: 10.1002/14651858.CD012592]">Wiffen 2017</a>). Our review will look for that outcome to allow comparability with opioids for cancer pain, as it was not an outcome reported in <a href="./references#CD014915-bbs2-0037" title="FisherE , MooreRA , FogartyAE , FinnDP , FinnerupNB , GilronI , et al. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain2021;162(Suppl 1):S45-66. [DOI: 10.1097/j.pain.0000000000001929]">Fisher 2021</a>. </p> <p>Potential positive effects of CbMs for people with cancer have to be balanced against potential adverse effects. One systematic review with pooled analysis of studies of CbMs for chronic pain emphasised the high rate of adverse effects with low (unfavourable) numbers needed to harm for central nervous system and psychiatric adverse effects (<a href="./references#CD014915-bbs2-0066" title="StockingsE , CampbellG , HallWD , NielsenS , ZagicD , RahmanR , et al. Cannabis and cannabinoids for the treatment of people with chronic non-cancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain2018;158:1932-54. [10.1097/j.pain.0000000000001293]">Stockings 2018</a>). <a href="./references#CD014915-bbs2-0037" title="FisherE , MooreRA , FogartyAE , FinnDP , FinnerupNB , GilronI , et al. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain2021;162(Suppl 1):S45-66. [DOI: 10.1097/j.pain.0000000000001929]">Fisher 2021</a> has combined all adverse effects in one analysis. </p> <p>In view of these considerable uncertainties, we have seen the need to update the literature and to assess the efficacy, tolerability and safety of CbMs compared to placebo or conventional medications for cancer pain. We concentrated on: </p> <p> <ul id="CD014915-list-0004"> <li> <p>additional participant‐reported outcomes beyond pain, such as sleep problems and mood;</p> </li> <li> <p>opioid‐sparing effects;</p> </li> <li> <p>central nervous system and psychiatric adverse effects.</p> </li> </ul> </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD014915-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD014915-sec-0014"></div> <p>To evaluate the benefits and harms of cannabis‐based medicines, including medical cannabis, for treating pain and other symptoms in adults with cancer compared to placebo or any other established analgesic for cancer pain. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD014915-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD014915-sec-0015"></div> <section id="CD014915-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD014915-sec-0017"> <h4 class="title">Types of studies</h4> <p>RCTs are the best design to minimise bias when evaluating the effectiveness of an intervention. We considered randomised, double‐blind (participants and physicians), controlled trials comparing CbMs and medical cannabis with placebo or any other established analgesic for cancer pain, according to the ladder scheme of the WHO (<a href="./references#CD014915-bbs2-0071" title="World Health Organization. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents, 2019. Available from www.who.int/ncds/management/palliative-care/cancer-pain-guidelines/en (accessed 21 June 2021).">WHO 2019</a>). Trials must have included participant‐reported pain outcomes. We included RCTs of any duration. The emphasis of the review was studies of two weeks or longer to try to obtain the efficacy outcome used in a previous overview of Cochrane Reviews on opioids for cancer pain (<a href="./references#CD014915-bbs2-0073" title="WiffenPJ , WeeB , DerryS , BellRF , MooreRA . Opioids for cancer pain – an overview of Cochrane Reviews. Cochrane Database of Systematic Reviews2017, Issue 7. Art. No: CD012592. [DOI: 10.1002/14651858.CD012592]">Wiffen 2017</a>). The clinical importance of experimental studies (one to three days' duration) and very short‐term studies (four to 13 days' duration) in chronic pain is limited. In addition, we considered studies in which CbMs are used as add‐on therapy to established analgesics, compared to these established analgesics without CbMs, and with participant‐reported pain outcomes. Studies had to include at least 10 participants per treatment arm (we made an ad hoc decision to change the method described in our protocol, which required 20 participants per treatment arm; <a href="#CD014915-sec-0230">Differences between protocol and review</a>; <a href="./references#CD014915-bbs2-0075" title="HäuserW , WelschP , RadbruchL , FisherE , BellRF , MooreRA . Cannabis-based medicines and medical cannabis for adults with cancer pain. Cochrane Database of Systematic Reviews2022, Issue 2. Art. No: CD014915. [DOI: 10.1002/14651858.CD014915]">Häuser 2022</a>). We included RCTs reporting at least one of our primary outcomes. </p> </section> <section id="CD014915-sec-0018"> <h4 class="title">Types of participants</h4> <p>Eligible studies included men and women (aged 18 years or older) of any race with cancer‐related pain (cancer pain or cancer therapy‐related pain, or both). We included all types and stages of cancer, in all settings, and receiving any type of cancer therapy. We included studies with mixed pain conditions, if the results for people with cancer‐related pain were reported separately. </p> </section> <section id="CD014915-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included CbMs (plant‐based CBs (CBD, dronabinol, nabiximols)), or synthetic CBs (nabilone) or medical cannabis (cannabis flowers or full spectrum cannabis extracts) at any dose or by any route that were administered for the relief of cancer pain. </p> <p>The comparison groups received placebo or other established analgesic medication for cancer pain. </p> <p>We did not consider experimental and non‐registered drugs such as CB receptor antagonists and negative allosteric modulators (e.g. rimonabant (SR141716A)) and modulators that increase or enhance endocannabinoid system activity (e.g. fatty acid amide hydrolase inhibitors) or synthetic CBs (e.g. levonantradol). </p> </section> <section id="CD014915-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD014915-sec-0021"> <h5 class="title">Primary outcomes</h5> <p>The proposed primary outcomes are the same as those used by <a href="./references#CD014915-bbs2-0073" title="WiffenPJ , WeeB , DerryS , BellRF , MooreRA . Opioids for cancer pain – an overview of Cochrane Reviews. Cochrane Database of Systematic Reviews2017, Issue 7. Art. No: CD012592. [DOI: 10.1002/14651858.CD012592]">Wiffen 2017</a> in the overview review of opioids for cancer pain. </p> <p> <ul id="CD014915-list-0005"> <li> <p>Proportion of participants reporting no worse than mild pain by 14 days after start of treatment (typically below 30/100 mm on a 100‐mm Visual Analogue Scale (VAS) or below 3 on an 11‐point Numeric Rating Scale (NRS)) as an acceptable outcome when their pain was moderate or severe (<a href="./references#CD014915-bbs2-0057" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut-offs – no worse than mild pain' as a simple, universal outcome. Anesthesia2013;68:400-12. [DOI: 10.1111/anae.12148]">Moore 2013</a>). </p> </li> <li> <p>Patient Global Impression of Change (PGIC) of much improved or very much improved.</p> </li> <li> <p>Withdrawals due to adverse events.</p> </li> </ul> </p> </section> <section id="CD014915-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD014915-list-0006"> <li> <p>Combined responder: number of participants who reported pain relief of 30% or greater and overall opioid use reduced or stable compared to baseline for parallel and cross‐over design studies and loss of this therapeutic response for studies with an enriched enrolment randomised withdrawal (EERW) design. </p> </li> <li> <p>Number of participants who reported pain relief of 30% or greater.</p> </li> <li> <p>Number of participants who reported pain relief of 50% or greater.</p> </li> <li> <p>Mean pain intensity: we preferentially extracted outcomes of numeric over visual pain scales. </p> </li> <li> <p>Sleep problems: we preferentially extracted outcomes of multidimensional questionnaires over single‐item questionnaires. </p> </li> <li> <p>Depression: we preferentially extracted outcomes of multidimensional questionnaires over single‐item questionnaires. </p> </li> <li> <p>Anxiety: we preferentially extracted outcomes of multidimensional questionnaires over single‐item questionnaires. </p> </li> <li> <p>Daily maintenance opioid dosage (mg morphine equivalent).</p> </li> <li> <p>Daily breakthrough opioid dosage (mg morphine equivalent).</p> </li> <li> <p>Number of participants dropping out due to lack of efficacy.</p> </li> <li> <p>All central nervous system adverse events according to the Medical Dictionary for Regulatory Activities (<a href="./references#CD014915-bbs2-0047" title="International Council for Harmonisation. Medical dictionary for regulatory activities version 23.1 (2020). Available from www.meddra.org/how-to-use/support-documentation/english (accessed 21 June 20217).">International Council for Harmonisation 2020</a>). </p> </li> <li> <p>All psychiatric adverse events according to the Medical Dictionary for Regulatory Activities (<a href="./references#CD014915-bbs2-0047" title="International Council for Harmonisation. Medical dictionary for regulatory activities version 23.1 (2020). Available from www.meddra.org/how-to-use/support-documentation/english (accessed 21 June 20217).">International Council for Harmonisation 2020</a>). </p> </li> <li> <p>Participants experiencing any serious adverse event.</p> </li> </ul> </p> </section> </section> </section> <section id="CD014915-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD014915-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases originally on 3 March 2022 and performed an updated search on 26 January 2023, without language or date restrictions. </p> <p> <ul id="CD014915-list-0007"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Library, Issue 1, 2023. </p> </li> <li> <p>MEDLINE (via Ovid) (1946 to 25 January 2023).</p> </li> <li> <p>Embase (via Ovid) (1974 to 25 January 2023).</p> </li> </ul> </p> <p>The search strategies used are outlined in <a href="./appendices#CD014915-sec-0223">Appendix 2</a>. The MEDLINE search strategy was independently peer‐reviewed when it was developed. We checked for retractions of included studies using the Retraction Watch database (<a href="http://retractiondatabase.org/" target="_blank">retractiondatabase.org/</a>). </p> </section> <section id="CD014915-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We reviewed the bibliographies of any RCTs identified. We searched the following clinical trials databases to identify additional published or unpublished data (all to 3 March 2022 and updated 27 January 2023). </p> <p> <ul id="CD014915-list-0008"> <li> <p>US National Institutes of Health ClinicalTrials.gov (<a href="http://www.ClinicalTrials.gov" target="_blank">www.ClinicalTrials.gov</a>) </p> </li> <li> <p>EU Clinical Trials Register (<a href="http://www.clinicaltrialsregister.eu" target="_blank">www.clinicaltrialsregister.eu</a>) </p> </li> <li> <p>WHO International Clinical Trials Registry Platform (ICTRP) (<a href="https://www.who.int/clinical-trials-registry-platform" target="_blank">www.who.int/clinical-trials-registry-platform</a>) </p> </li> </ul> </p> <p>In addition, we searched grey literature, checked reference lists of reviews and retrieved articles for additional studies, and performed citation searches on key articles. We contacted experts in the field for unpublished and ongoing trials. We did not contact study authors for additional information. </p> </section> </section> <section id="CD014915-sec-0026"> <h3 class="title" id="CD014915-sec-0026">Data collection and analysis</h3> <section id="CD014915-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Three review authors (EF, LR, WH) independently determined eligibility by reading the abstract and title of each study identified by the search. They eliminated studies that clearly did not satisfy the inclusion criteria, and obtained full copies of the remaining studies. Two review authors (RFB, WH) independently read these studies and reached agreement by discussion. Consulting a third review author (PW) was not necessary because there was no disagreement on the inclusion and exclusion of studies. We did not anonymise the studies before assessment. We created a PRISMA flow chart (<a href="./references#CD014915-bbs2-0054" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLOS Medicine2009;6:e1000097. [DOI: 10.1371/journal.pmed1000097]">Moher 2009</a>). </p> </section> <section id="CD014915-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (PW, WH) independently extracted data using a prepiloted standard form and checked for agreement before entering data into Review Manager 5 (<a href="./references#CD014915-bbs2-0062" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). Three review authors (PW, RFB, WH) independently extracted information about the study funding sources and study author conflicts of interest, the cancer condition, number of participants treated, study setting, inclusion and exclusion criteria, demographic and clinical characteristics of the study samples (age, gender, race, pain baseline), prior recreational cannabis use, drug and dosing regimen, cotherapies allowed, rescue medication, study design (placebo or active control), study duration and follow‐up, analgesic outcome measures and results, withdrawals, and adverse events (participants experiencing any adverse event or serious adverse effect). We analysed the nature of all serious adverse events. We analysed the nature of all adverse events, but concentrated on those that are regarded to be most relevant adverse events of CbMs and MC, namely central nervous system and psychiatric adverse events. </p> </section> <section id="CD014915-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (RFB, WH) independently assessed risk of bias for each study using the Cochrane RoB 1 tool, using the criteria outlined in the 2011 edition of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014915-bbs2-0041" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We also used criteria adapted from those used by the Pain, Palliative and Supportive Care Review Group (group was closed in 2023) for reviews on medication therapy for cancer pain, with any disagreements resolved by discussion. Consulting a third review author (PW) was not necessary because there was no disagreement on the risk of bias assessment. </p> <p>We assessed the following risks of bias for each study as follows.</p> <p> <ul id="CD014915-list-0009"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (i.e. any truly random process, e.g. random number table; computer random number generator); unclear risk of bias (when the method used to generate the sequence was not clearly stated); high risk of bias (studies used a non‐random process (e.g. odd or even date of birth; hospital or clinic record number)). </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during, recruitment, or changed after assignment. We assessed the methods as: low risk of bias (e.g. telephone or central randomisation; consecutively numbered, sealed, opaque envelopes); unclear risk of bias (when method was not clearly stated). We excluded studies that did not conceal allocation and were, therefore, at high risk of bias (e.g. open list). </p> </li> <li> <p>Blinding of participants and personnel/treatment providers (systematic performance bias). We assessed the methods used to blind participants and personnel/treatment providers from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study stated that it was blinded and described the method used to achieve blinding, e.g. identical tablets; matched in appearance and smell); unclear risk of bias (study stated that it was blinded but did not provide an adequate description of how it was achieved); high risk of bias (blinding of participants was not ensured, e.g. tablets different in form or taste). </p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study stated that outcome assessors were blinded to the intervention or exposure status of participants); unclear risk of bias (study stated that the outcome assessors were blinded but did not provide an adequate description of how it was achieved); high risk of bias (outcome assessors knew the intervention or exposure status of participants). </p> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk of bias (i.e. less than 10% participant dropout or used 'baseline observation carried forward' analysis, or both); unclear risk of bias (used 'last observation carried forward' (LOCF) analysis); or high risk of bias (used 'completer' analysis). </p> </li> <li> <p>Reporting bias due to selective outcome reporting (reporting bias). We checked if a study protocol before the start of the study was available and if all outcomes of the study protocol were reported in the publications of the study. There was low risk of reporting bias if the study protocol was available and all the study's prespecified (primary and secondary) outcomes that were of interest in the review were reported in the prespecified way, or if the study protocol was not available, but it was clear that the published reports included all expected outcomes, including those that were prespecified (convincing text of this nature may be uncommon). We judged high risk of reporting bias if not all the study's prespecified primary outcomes were reported; one or more primary outcomes was reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not prespecified; one or more reported primary outcomes were not prespecified (unless clear justification for their reporting was provided, such as an unexpected adverse effect); one or more outcomes of interest in the review were reported incompletely so that they could not be entered in a meta‐analysis; the study report did not include results for a key outcome that would be expected to have been reported for such a study. We judged unclear risk of bias if there was insufficient information to permit judgement of 'low risk' or 'high risk'. </p> </li> <li> <p>In addition to the original risk of bias criteria outlined in the 2011 edition of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014915-bbs2-0041" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>), we assessed 'Group similarity at baseline' (selection bias) as another risk of bias. We assessed similarity of the study groups at baseline for the most important prognostic clinical and demographic indicators. We judged low risk of bias if groups were similar at baseline for demographic factors, value of main outcome measure(s) and important prognostic factors. We judged unclear risk of bias if important prognostic clinical and demographic indicators were not reported. We judged high risk of bias if groups were not similar at baseline for demographic factors, value of main outcome measure(s) and important prognostic factors. </p> </li> </ul> </p> <p>We also assessed overall risk of bias in each trial according to guidance in the current edition of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014915-bbs2-0043" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Higgins 2021</a>). </p> <p> <ul id="CD014915-list-0010"> <li> <p><b>Low risk of bias:</b> the trial was judged to be at low risk of bias for all domains for this result. </p> </li> <li> <p><b>Some concerns:</b> the trial was judged to raise some concerns in at least one domain for this result, but not to be at high risk for any domain for this result. </p> </li> <li> <p><b>High risk of bias:</b> the trial was judged to be at high risk of bias in at least one domain for this result or the judged to raise some concerns in multiple domains for this result in a way that substantially lowers confidence in the result. </p> </li> </ul> </p> </section> <section id="CD014915-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated numbers needed to treat for an additional beneficial outcome (NNTB) as the reciprocal of the absolute risk reduction (ARR) (<a href="./references#CD014915-bbs2-0053" title="McQuayH , MooreR . An Evidence-Based Resource for Pain Relief. Oxford (UK): Oxford University Press, 1998. [ISBN:0–19–263048–2]">McQuay 1998</a>). For unwanted effects, the NNTB becomes the number needed to treat for an additional harmful outcome (NNTH) and is calculated in the same manner. We used dichotomous data to calculate risk differences (RD) with 95% confidence intervals (CIs) using a fixed‐effect model unless we found significant statistical or clinical heterogeneity (see below). We set the threshold for a clinically relevant benefit or a clinically relevant harm for categorical variables by an NNTB or NNTH less than 10 (<a href="./references#CD014915-bbs2-0056" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: Systematic Reviews in Pain Research: Methodology Refined. Washington (DC): IASP Press, 2008:15-24. [ISBN: 978–0–931092–69–5]">Moore 2008</a>). </p> <p>We calculated standardised mean differences (SMD) with 95% CIs for continuous variables, using a random‐effects model. We used Cohen's categories to evaluate the magnitude of the effect size, calculated by SMD, with Hedges' g value of 0.2 = small, 0.5 = medium and 0.8 = large (<a href="./references#CD014915-bbs2-0030" title="CohenJ . Statistical Power Analysis for the Behavioral Sciences. Hillsdale (NJ): Lawrence Erlbaum Associates, 1988.">Cohen 1988</a>). We labelled a g value less than 0.2 to be a 'not substantial' effect size. We assumed a minimally important difference if the Hedges' g value was 0.2 or greater (<a href="./references#CD014915-bbs2-0036" title="FayersPM , HaysRD . Don't middle your MIDs: regression to the mean shrinks estimates of minimally important differences. Quality of Life Research2014;23:1-4. [DOI: 10.1007/s11136-013-0443]">Fayers 2014</a>). To increase interpretability, we analysed the mean difference of mean pain intensity. If needed, we converted 0 to 10 and 0 to 100 NRS or VAS to a single scale. </p> </section> <section id="CD014915-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>For studies with more than two arms, we split the control treatment arm between active treatment arms in a single study if the active treatment arms could not to be combined for analysis. We included studies with a cross‐over design where separate data from the two periods were reported, data were presented that excluded a significant carry‐over effect or statistical adjustments were carried out in case of a significant carry‐over effect. We did not anticipate cluster trials for this intervention. </p> </section> <section id="CD014915-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We used intention‐to‐treat (ITT) analysis where the ITT population consisted of participants who were randomised, took at least one dose of the assigned study medication and provided at least one postbaseline assessment. Where means or standard deviations (SDs) were missing, we attempted to obtain these data through contacting trial authors. Where SDs were not available from trial authors, we calculated them from t‐values, P values, CIs or standard errors, where reported by the studies (<a href="./references#CD014915-bbs2-0042" title="HigginsJP , LiT , DeeksJJ . Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from handbook: training.cochrane.org/handbook/archive/v6.1.">Higgins 2020a</a>). Where rates of pain relief of 30% or greater and of 50% or greater were not reported or provided on request, we calculated them from means and SDs using a validated imputation method (<a href="./references#CD014915-bbs2-0039" title="FurukawaTA , CiprianiA , BarbuiC , BrambillaP , WatanabeN . Imputing response rates from means and standard deviations in meta-analyses. International Clinical Psychopharmacology2005;20:49-52. [DOI: 10.1097/00004850-200501000-00010]">Furukawa 2005</a>). </p> </section> <section id="CD014915-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We dealt with clinical heterogeneity by combining studies that examined similar conditions. We assessed statistical heterogeneity using the I<sup>2</sup> statistic. Where the I<sup>2</sup> value was greater than 50%, we considered possible reasons for this. </p> </section> <section id="CD014915-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed publication bias using a method designed to detect the amount of unpublished data with a null effect required to make any result clinically irrelevant (usually taken to mean an NNTB of 10 or higher) (<a href="./references#CD014915-bbs2-0056" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: Systematic Reviews in Pain Research: Methodology Refined. Washington (DC): IASP Press, 2008:15-24. [ISBN: 978–0–931092–69–5]">Moore 2008</a>). </p> </section> <section id="CD014915-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We used a random‐effects model, using the inverse variance method in Review Manager 5 for meta‐analysis, because we expected clinical heterogeneity due to the different types of cancer pain conditions (<a href="./references#CD014915-bbs2-0062" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). </p> </section> <section id="CD014915-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We intended to perform subgroup analyses for the primary outcomes according to the following, where there were at least two studies available. </p> <p> <ul id="CD014915-list-0011"> <li> <p>Different types of CbMs.</p> </li> <li> <p>Different dosages of the same CbM and study duration. We distinguished between short‐term (four to 12 weeks), intermediate‐term (13 to 26 weeks) and long‐term (more than 26 weeks) studies (<a href="./references#CD014915-bbs2-0029" title="ChaparroLE , FurlanAD , DeshpandeA , Mailis-GagnonA , AtlasS , TurkDC . Opioids compared to placebo or other treatments for chronic low-back pain. Cochrane Database of Systematic Reviews2013, Issue 8. Art. No: CD004959. [DOI: 10.1002/14651858.CD004959.pub4]">Chaparro 2013</a>), as well as experimental studies (one to three days) and very short‐term (three to 13 days) studies. </p> </li> <li> <p>Types of controls (placebo; established analgesic).</p> </li> <li> <p>Types of cancer‐related pain (pain directly caused by cancer, e.g. by bone metastases versus pain caused by cancer treatment, e.g. chemotherapy‐induced polyneuropathy). </p> </li> </ul> </p> <p>These subgroup analyses were predefined due to the many uncertainties about CbMs for chronic pain, such as the selection of the type of CbM (cannabis flowers versus CBs), optimal dosage for efficacy, duration of efficacy, and comparative efficacy and safety to established medications (<a href="./references#CD014915-bbs2-0037" title="FisherE , MooreRA , FogartyAE , FinnDP , FinnerupNB , GilronI , et al. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain2021;162(Suppl 1):S45-66. [DOI: 10.1097/j.pain.0000000000001929]">Fisher 2021</a>; <a href="./references#CD014915-bbs2-0045" title="HäuserW , FinnDP , KalsoE , Krcevski-SkvarcN , KressHG , MorlionB , et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. European Journal of Pain2018;22:1547-64. [DOI: 10.1002/ejp.1297]">Häuser 2018</a>). </p> <p>Because of the relevant differences of study designs and purposes of the studies, we decided not to pool all studies. Instead, we conducted four separate analyses. </p> </section> <section id="CD014915-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We performed a sensitivity analysis by excluding studies with imputed rates of pain relief of 30% or greater. We did not conduct the planned sensitivity analysis by excluding studies with imputed rates of pain relief of 50% or greater because all rates of pain relief of 50% or greater had to be calculated by an imputation method. The planned sensitivity analysis excluding studies with less than 14 days' duration was not necessary because we did not pool studies with a duration of less and of more than 14 days. </p> </section> <section id="CD014915-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>Two review authors (EF, WH) independently rated the certainty of the body of evidence for the outcomes. We resolved discrepancies by consulting a third review author (RAM). We used the GRADE system to rank the certainty of the evidence using the guidelines provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014915-bbs2-0064" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , ElieAE , SkoetzN , et al. Chapter 14. Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from handbook: training.cochrane.org/handbook/archive/v6.1.">Schünemann 2020</a>) and the GRADE Handbook (<a href="./references#CD014915-bbs2-0063" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>). </p> <p>The GRADE system considers study design as a marker of quality. It uses the following criteria for assigning a certainty level to the body of evidence for a given outcome. </p> <p> <ul id="CD014915-list-0012"> <li> <p><b>High:</b> randomised trials without downgrading or double‐upgraded observational studies </p> </li> <li> <p><b>Moderate:</b> downgraded randomised trials or upgraded observational studies </p> </li> <li> <p><b>Low:</b> double‐downgraded randomised trials or observational studies without downgrading </p> </li> <li> <p><b>Very low:</b> triple‐downgraded randomised trials, downgraded observational studies or case series/case reports </p> </li> </ul> </p> <p>Factors that may decrease the certainty level of a body of evidence are as follows.</p> <p> <ul id="CD014915-list-0013"> <li> <p>Limitations in the design and implementation of available studies, suggesting high likelihood of bias. We assumed that there were limitations in study design if more than 50% of participants were from studies with high risk of bias, as defined by the Cochrane RoB 1 tool (<a href="./references#CD014915-bbs2-0041" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). </p> </li> <li> <p>Indirectness of evidence (indirect population, intervention, control, outcomes). We assessed if the study population was different from the population in routine clinical care by assessing if studies excluded participants with relevant medical conditions (cardiovascular, hepatic, renal and endocrine system). If exclusion of participants with clinically relevant medical conditions resulted in 50% or more of the total number of participants, we decreased the certainty of evidence. </p> </li> <li> <p>Unexplained heterogeneity (I<sup>2</sup> greater than 50%) or inconsistency of results. </p> </li> <li> <p>Imprecision of results (wide CIs; low number of events).</p> </li> <li> <p>High probability of publication bias. We assumed a potential publication bias if all studies were initiated and funded by the manufacturer of the drug tested in the trial. </p> </li> </ul> </p> <p>We used the GRADE system criteria for assigning the grade of evidence (<a href="./references#CD014915-bbs2-0063" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>). </p> <p> <ul id="CD014915-list-0014"> <li> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different. </p> </li> <li> <p><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> <p>We created one summary of findings table to present in a transparent and simple tabular format the main findings for comparisons of CbMs and medical cannabis with placebo or any established analgesic. In particular, we included key information concerning the certainty of evidence, the magnitude of effect of the interventions examined and the sum of available data on these outcomes: </p> <p> <ul id="CD014915-list-0015"> <li> <p>proportion of participants reporting no worse than mild pain by 14 days after start of treatment; </p> </li> <li> <p>PGIC of much improved or very much improved;</p> </li> <li> <p>withdrawals due to adverse events;</p> </li> <li> <p>mean pain intensity;</p> </li> <li> <p>daily maintenance opioid dosage (mg morphine equivalent);</p> </li> <li> <p>daily breakthrough opioid dosage (mg morphine equivalent);</p> </li> <li> <p>participants experiencing any serious adverse event.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD014915-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD014915-sec-0039"></div> <section id="CD014915-sec-0040"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD014915-sec-0232" title="">Characteristics of included studies</a>; <a href="./references#CD014915-sec-0233" title="">Characteristics of excluded studies</a>; and <a href="./references#CD014915-sec-0234" title="">Characteristics of ongoing studies</a> tables. </p> <section id="CD014915-sec-0041"> <h4 class="title">Results of the search</h4> <p>The searches (performed 3 March 2022, updated 26 January 2023) produced 966 records We identified 145 potentially relevant studies in CENTRAL, 433 in MEDLINE, 246 in Embase, 121 in the ClinicalTrials.gov, nine in the EU Clinical Trials Register and 12 in the WHO ICTRP. A search for studies in the International Association for Cannabinoid Medicines (IACM) databank was not possible because the database was no longer available. We identified 38 additional records through other sources. After removing duplicates, we read the titles and abstracts of 297 articles and excluded studies that were clearly irrelevant. We read the full text of 18 potentially eligible articles and included 14 studies in the review (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>; <a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a>; <a href="./references#CD014915-bbs2-0004" title="HardyJ , GreerR , HugegettG , KearneyA , GurgenicT , GoodP . Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). Journal of Clinical Oncology2023;41(7):1444-52. [DOI: 10.1200/JCO.22.]">Hardy 2023</a>; <a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>; <a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>; <a href="./references#CD014915-bbs2-0008" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal Pain and Symptom Management2014;47:166-73. [DOI: 10.1016/j.jpainsymman.2013.02.018]">Lynch 2014</a>; <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>; <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>; <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>) (see <a href="#CD014915-fig-0001">Figure 1</a>). We excluded one study with reasons (see <a href="./references#CD014915-sec-0233" title="">Characteristics of excluded studies</a> table) and identified five ongoing studies (see <a href="./references#CD014915-sec-0234" title="">Characteristics of ongoing studies</a> table). No studies are awaiting classification. </p> <div class="figure" id="CD014915-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD014915-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>Four studies with nabiximols for opioid refractory cancer pain (<a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>), and four experimental studies with a synthetic THC analogue (<a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>; <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>), were suited for quantitative analysis. Six studies were included only in qualitative analysis: one study employed a withdrawal design (<a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a>). The heterogeneity of the aims of four studies (reducing chemotherapy induced neuropathic pain (<a href="./references#CD014915-bbs2-0008" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal Pain and Symptom Management2014;47:166-73. [DOI: 10.1016/j.jpainsymman.2013.02.018]">Lynch 2014</a>), improving health‐related quality of life (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>), reducing cachexia (<a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>), and total symptom burden (<a href="./references#CD014915-bbs2-0004" title="HardyJ , GreerR , HugegettG , KearneyA , GurgenicT , GoodP . Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). Journal of Clinical Oncology2023;41(7):1444-52. [DOI: 10.1200/JCO.22.]">Hardy 2023</a>)), and the different medications used prohibited quantitative synthesis (<a href="./references#CD014915-bbs2-0008" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal Pain and Symptom Management2014;47:166-73. [DOI: 10.1016/j.jpainsymman.2013.02.018]">Lynch 2014</a>: nabiximols; <a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>; <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>: synthetic THC analogue (nabilone); <a href="./references#CD014915-bbs2-0004" title="HardyJ , GreerR , HugegettG , KearneyA , GurgenicT , GoodP . Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). Journal of Clinical Oncology2023;41(7):1444-52. [DOI: 10.1200/JCO.22.]">Hardy 2023</a>: CBD). The reported outcomes of one experimental study with synthetic THC analogue was not suited for quantitative analysis (<a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>). </p> </section> <section id="CD014915-sec-0042"> <h4 class="title">Included studies</h4> <section id="CD014915-sec-0043"> <h5 class="title">Characteristics of the studies</h5> <p>We included 14 studies with 20 treatment arms involving 1823 participants into the analysis. The studies of <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a> and <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a> involved different populations. Four studies involving different participants were reported in two publications (<a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a>; <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>). </p> <section id="CD014915-sec-0044"> <h6 class="title">Aims of the studies</h6> <p>Five studies tested if nabiximols was effective as an add‐on therapy for people with cancer pain not adequately relieved by opioids (<a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a>; <a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>). Five studies tested if a single dose of synthetic THC analogue relieved moderate‐to‐severe cancer pain after stopping other analgesics four hours before the intake of synthetic THC analogue (<a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>; <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>; <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>). One study tested nabiximols for chemotherapy‐induced neuropathic pain (<a href="./references#CD014915-bbs2-0008" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal Pain and Symptom Management2014;47:166-73. [DOI: 10.1016/j.jpainsymman.2013.02.018]">Lynch 2014</a>). Two studies tested a synthetic THC analogue (nabilone) to reduce cancer and radiochemotherapy‐related symptoms (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>; <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>). One study tested CBD to reduce total symptom burden in advanced cancer (<a href="./references#CD014915-bbs2-0004" title="HardyJ , GreerR , HugegettG , KearneyA , GurgenicT , GoodP . Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). Journal of Clinical Oncology2023;41(7):1444-52. [DOI: 10.1200/JCO.22.]">Hardy 2023</a>). Thus, the aim of one study was to reduce cancer therapy‐related pain (<a href="./references#CD014915-bbs2-0008" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal Pain and Symptom Management2014;47:166-73. [DOI: 10.1016/j.jpainsymman.2013.02.018]">Lynch 2014</a>), of two studies to reduce cancer‐related and cancer therapy‐related pain (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>; <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>), and of the remaining studies to reduce cancer‐related pain. </p> </section> <section id="CD014915-sec-0045"> <h6 class="title">Study setting</h6> <p>We found eight studies used a single‐centre recruitment strategy (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>; <a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>; <a href="./references#CD014915-bbs2-0008" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal Pain and Symptom Management2014;47:166-73. [DOI: 10.1016/j.jpainsymman.2013.02.018]">Lynch 2014</a>; <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>; <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>; <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>), the remaining studies were multicentre. The number of study centres ranged between 20 and 114. Six studies were conducted in North America (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>; <a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>; <a href="./references#CD014915-bbs2-0008" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal Pain and Symptom Management2014;47:166-73. [DOI: 10.1016/j.jpainsymman.2013.02.018]">Lynch 2014</a>; <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>), two in Belgium (<a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>), one in Australia (<a href="./references#CD014915-bbs2-0004" title="HardyJ , GreerR , HugegettG , KearneyA , GurgenicT , GoodP . Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). Journal of Clinical Oncology2023;41(7):1444-52. [DOI: 10.1200/JCO.22.]">Hardy 2023</a>), and one in Mexico (<a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>). The remaining studies were conducted across two continents: <a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; and <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a> included participants from North America and Europe and <a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a> from Europe and Asia. </p> </section> <section id="CD014915-sec-0046"> <h6 class="title">Study design</h6> <p>Seven studies used a parallel design (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>; <a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0004" title="HardyJ , GreerR , HugegettG , KearneyA , GurgenicT , GoodP . Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). Journal of Clinical Oncology2023;41(7):1444-52. [DOI: 10.1200/JCO.22.]">Hardy 2023</a>; <a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>; <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>), six studies had a cross‐over design (<a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>; <a href="./references#CD014915-bbs2-0008" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal Pain and Symptom Management2014;47:166-73. [DOI: 10.1016/j.jpainsymman.2013.02.018]">Lynch 2014</a>; <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>; <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>), and one study had a withdrawal design (<a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a>). The one‐day studies tested two and three dosages of a synthetic THC analogue (<a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>; <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>; <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>). One study had one THC and one THC/CBD arm (<a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>). One study had three THC/CBD arms with different dosages (<a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>). </p> </section> <section id="CD014915-sec-0047"> <h6 class="title">Study duration</h6> <p>We found five experimental studies with one dose lasting less than one day (<a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>; <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>; <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>). The double‐blind period was two weeks in one study (<a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>), five weeks in four studies (<a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>), and eight weeks in three studies (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>; <a href="./references#CD014915-bbs2-0008" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal Pain and Symptom Management2014;47:166-73. [DOI: 10.1016/j.jpainsymman.2013.02.018]">Lynch 2014</a>; <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>). </p> </section> <section id="CD014915-sec-0048"> <h6 class="title">Sample sizes</h6> <p>The sample sizes ranged between 10 and 399. Eight studies had treatment group sizes below 50 participants (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>; <a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>; <a href="./references#CD014915-bbs2-0008" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal Pain and Symptom Management2014;47:166-73. [DOI: 10.1016/j.jpainsymman.2013.02.018]">Lynch 2014</a>; <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>; <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>; <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>). The remaining six were between 50 and 200 participants in each treatment group (<a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a>; <a href="./references#CD014915-bbs2-0004" title="HardyJ , GreerR , HugegettG , KearneyA , GurgenicT , GoodP . Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). Journal of Clinical Oncology2023;41(7):1444-52. [DOI: 10.1200/JCO.22.]">Hardy 2023</a>; <a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>). Treatment group sizes were of the order of 200 participants or more in two studies (<a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>). </p> </section> <section id="CD014915-sec-0049"> <h6 class="title">Study period</h6> <p>Two studies reported the study period which was 2005 to 2007 (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>) and 2017 to 2019 (<a href="./references#CD014915-bbs2-0004" title="HardyJ , GreerR , HugegettG , KearneyA , GurgenicT , GoodP . Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). Journal of Clinical Oncology2023;41(7):1444-52. [DOI: 10.1200/JCO.22.]">Hardy 2023</a>). </p> </section> <section id="CD014915-sec-0050"> <h6 class="title">Study funding</h6> <p>Four studies received public funding (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>; <a href="./references#CD014915-bbs2-0004" title="HardyJ , GreerR , HugegettG , KearneyA , GurgenicT , GoodP . Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). Journal of Clinical Oncology2023;41(7):1444-52. [DOI: 10.1200/JCO.22.]">Hardy 2023</a>; <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>). Pharmaceutical companies funded four studies (<a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a>; <a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>). Two studies received public and pharmaceutical company funding (<a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>). Two studies received no funding (<a href="./references#CD014915-bbs2-0008" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal Pain and Symptom Management2014;47:166-73. [DOI: 10.1016/j.jpainsymman.2013.02.018]">Lynch 2014</a>; <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>). Two studies did not report on funding (<a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>). </p> </section> <section id="CD014915-sec-0051"> <h6 class="title">Conflicts of interest</h6> <p>Authors of seven studies reported that they had no conflicts of interest (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>; <a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a>; <a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>; <a href="./references#CD014915-bbs2-0008" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal Pain and Symptom Management2014;47:166-73. [DOI: 10.1016/j.jpainsymman.2013.02.018]">Lynch 2014</a>; <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>). Authors of six studies did not report on conflicts of interest (<a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>; <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>; <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>). Authors of one study reported on conflicts of interest (<a href="./references#CD014915-bbs2-0004" title="HardyJ , GreerR , HugegettG , KearneyA , GurgenicT , GoodP . Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). Journal of Clinical Oncology2023;41(7):1444-52. [DOI: 10.1200/JCO.22.]">Hardy 2023</a>). </p> </section> </section> <section id="CD014915-sec-0052"> <h5 class="title">Characteristics of participants</h5> <section id="CD014915-sec-0053"> <h6 class="title">Age</h6> <p>The mean age of the participants was between 55 and 60 years. Two studies reported the range of age which was 21 to 75 years (<a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>). </p> </section> <section id="CD014915-sec-0054"> <h6 class="title">Gender</h6> <p>The percentage of men was between 17% and 93%. Two studies did not report gender (<a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>). </p> </section> <section id="CD014915-sec-0055"> <h6 class="title">Types of cancer and of cancer pain</h6> <p>The studies included mainly participants with carcinoma. One study included participants with squamous cell carcinoma of the head and neck (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>), and one study included participants with non‐small cell lung cancer (<a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>). Four studies reported the percentage of participants with different types of cancer pain (e.g. nociceptive, neuropathic, visceral) (<a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a>; <a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>). One study included participants with chemotherapy‐induced neuropathic pain (<a href="./references#CD014915-bbs2-0008" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal Pain and Symptom Management2014;47:166-73. [DOI: 10.1016/j.jpainsymman.2013.02.018]">Lynch 2014</a>). </p> </section> <section id="CD014915-sec-0056"> <h6 class="title">Inclusion criteria</h6> <p>One study did not report on a required pain intensity for inclusion (<a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>). The inclusion criteria of three studies were not based on pain intensity. Of these, one study did not report baseline pain values (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>). Two studies indicated a moderate pain intensity with a large SD and thus included some participants with a lower pain intensity (<a href="./references#CD014915-bbs2-0004" title="HardyJ , GreerR , HugegettG , KearneyA , GurgenicT , GoodP . Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). Journal of Clinical Oncology2023;41(7):1444-52. [DOI: 10.1200/JCO.22.]">Hardy 2023</a>; <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>). The remaining studies required at least moderate pain intensity for inclusion, of which four studies required moderate pain intensity despite opioid therapy (<a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a>; <a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>). </p> </section> <section id="CD014915-sec-0057"> <h6 class="title">Exclusion criteria</h6> <p>Eight studies excluded people with major internal diseases (e.g. of the heart, liver) (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>; <a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a>; <a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>; <a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>; <a href="./references#CD014915-bbs2-0008" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal Pain and Symptom Management2014;47:166-73. [DOI: 10.1016/j.jpainsymman.2013.02.018]">Lynch 2014</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>). Five studies excluded people with major psychiatric disorders (e.g. psychosis, substance‐use disorder) (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>; <a href="./references#CD014915-bbs2-0004" title="HardyJ , GreerR , HugegettG , KearneyA , GurgenicT , GoodP . Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). Journal of Clinical Oncology2023;41(7):1444-52. [DOI: 10.1200/JCO.22.]">Hardy 2023</a>; <a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>; <a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>). Five studies excluded people with cannabis use (<a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>; <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>). Five studies excluded people with "large dosages of narcotics" without defining the type of narcotic and the threshold of a large dosage (<a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>; <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>; <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>). </p> </section> <section id="CD014915-sec-0058"> <h6 class="title">Previous experience of participants with herbal cannabis</h6> <p>Two studies reported on previous cannabis experience (12% of participants in both studies) without making a distinction between recreational and medical use (<a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>). </p> </section> </section> <section id="CD014915-sec-0059"> <h5 class="title">Characteristics of the treatment delivered</h5> <section id="CD014915-sec-0060"> <h6 class="title">Types and doses of cannabis‐based medicines and comparators</h6> <p>Five studies used flexible oromucosal nabiximols with 'medium' dosages (THC/CBD up to 27/24 mg/day) (<a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>; <a href="./references#CD014915-bbs2-0008" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal Pain and Symptom Management2014;47:166-73. [DOI: 10.1016/j.jpainsymman.2013.02.018]">Lynch 2014</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>). One study included a treatment arm with 'low‐dose' THC/CBD (up to 10.8/10 mg/day). One study included an arm with 'high‐dose' THC/CBD (up to 42.2/40 mg/day) (<a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>). One study arm used a 'medium' dosage of THC (up to 27 mg/day) (<a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>). The experimental studies tested different fixed dosages of synthetic THC analogue orally (4 mg/day, 5 mg/day, 10 mg/day and 20 mg/day) (<a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>; <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>; <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>). The fixed dosages of nabilone orally were within the recommended range with 1 mg/day (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>), and 2 mg/day (<a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>). The median daily dose in the study with oral CBD oil was 400 mg/day. All studies compared CbMs to placebo. The experimental studies also compared CbMs to codeine 50 mg/day, 60 mg/day and 120 mg/day (<a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>; <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>). </p> </section> <section id="CD014915-sec-0061"> <h6 class="title">Rescue medication</h6> <p>Three studies used opioids as rescue medication. The study authors did not report the dosages of rescue medication used in the study groups (<a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>). The single dosage studies did not use rescue medication (<a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>; <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>; <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>). The remaining studies did not report on the type of rescue medication (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>; <a href="./references#CD014915-bbs2-0004" title="HardyJ , GreerR , HugegettG , KearneyA , GurgenicT , GoodP . Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). Journal of Clinical Oncology2023;41(7):1444-52. [DOI: 10.1200/JCO.22.]">Hardy 2023</a>; <a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>; <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>). </p> </section> </section> </section> <section id="CD014915-sec-0062"> <h4 class="title">Excluded studies</h4> <p>We excluded one study after full‐text review because it did not include a study arm as required by our inclusion criteria (placebo or other active medication) (<a href="./references#CD014915-bbs2-0015" title="ZyllaDM , EklundJ , GilmoreG , GavendaA , GuggisbergJ , VazquezBenitezG , et al. A randomised trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction. Supportive Care in Cancer2021;29(12):7471-8. ">Zylla 2021</a>). </p> </section> <section id="CD014915-sec-0063"> <h4 class="title">Ongoing studies</h4> <p>We identified five ongoing studies with unpublished results; two studies used medical cannabis, either by oral liquid (<a href="./references#CD014915-bbs2-0016" title="ACTRN12619001534178. A phase I/II double-blind, randomised controlled trial assessing effect of medicinal cannabis on quality of life and symptom control in advanced cancer. anzctr.org.au/ACTRN12619001534178.aspx (first received 30 September 2019). [anzctr.org.au/ACTRN12619001534178.aspx]">ACTRN12619001534178</a>) or by inhalation (<a href="./references#CD014915-bbs2-0020" title="NCT04042545. Safety and efficacy of inhaled cannabis for the uncontrolled pain relief in patients with advanced cancer (PLENITUDE). clinicaltrials.gov/ct2/show/NCT04042545 (first received 2 August 2019). [clinicaltrials.gov/ct2/show/NCT04042545]">NCT04042545</a>) application, and three studies used THC/CBD, either by orobuccal (<a href="./references#CD014915-bbs2-0017" title="ACTRN12621001302842. NanaBis™ an oro-buccal administered delta9-tetrahydrocannabinol (d9-THC) and cannabidiol (CBD) medicine for the management of chronic pain from metastatic bone cancer. anzctr.org.au/ACTRN12621001302842.aspx (first received 14 April 2021). [anzctr.org.au/ACTRN12621001302842.aspx]">ACTRN12621001302842</a>) or oral liquid application (<a href="./references#CD014915-bbs2-0018" title="EudraCT 001382-32. A double-blind, randomized phase 1/2 study to assess the efficacy and safety of BCT-521 versus placebo for pain associated with cancer inpatients already receiving standard of care treatment with opioids. www.clinicaltrialsregister.eu/ctr-search/trial/2019-001382-32/PL/ (first received 1 August 2019). ">EudraCT 001382‐32</a>; <a href="./references#CD014915-bbs2-0019" title="HardyJ , HaywoodA , GognaG , MartinJ , YatesP , GreerR , et al. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Trials2020;21:611. [DOI: 10.1186/s13063-020-04541-6]">Hardy 2020</a>). </p> </section> </section> <section id="CD014915-sec-0064"> <h3 class="title">Risk of bias in included studies</h3> <p>We judged risk of bias across most domains as unclear (<a href="#CD014915-fig-0002">Figure 2</a>; <a href="#CD014915-fig-0003">Figure 3</a>; see <a href="./references#CD014915-sec-0232" title="">Characteristics of included studies</a> table for detailed information regarding risk of bias assessments of each study). We rated the overall risk of bias according to guidance in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD014915-bbs2-0043" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Higgins 2021</a>). Five studies were at unclear overall risk of bias (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>; <a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>; <a href="./references#CD014915-bbs2-0008" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal Pain and Symptom Management2014;47:166-73. [DOI: 10.1016/j.jpainsymman.2013.02.018]">Lynch 2014</a>), and the overall risk of bias was high in the remaining studies (<a href="./references#CD014915-bbs2-0004" title="HardyJ , GreerR , HugegettG , KearneyA , GurgenicT , GoodP . Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). Journal of Clinical Oncology2023;41(7):1444-52. [DOI: 10.1200/JCO.22.]">Hardy 2023</a>; <a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>; <a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>; <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>; <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>). No trial was at low risk of bias for all categories examined. </p> <div class="figure" id="CD014915-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD014915-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD014915-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD014915-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD014915-sec-0065"> <h4 class="title">Allocation</h4> <section id="CD014915-sec-0066"> <h5 class="title">Random sequence generation (selection bias)</h5> <p>We judged one study at low risk of random sequence generation (<a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>). There were concerns for the remaining studies, which did not report the details of random sequence generation (unclear risk). </p> </section> <section id="CD014915-sec-0067"> <h5 class="title">Allocation concealment (selection bias)</h5> <p>No studies described allocation concealment adequately. Therefore, we judged all studies at unclear risk of bias. </p> </section> </section> <section id="CD014915-sec-0068"> <h4 class="title">Blinding</h4> <p>We judged blinding of participants and personnel as low risk of bias in six studies (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>; <a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a>; <a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>; <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>). There were some concerns for the studies for seven studies, which reported no details of the blinding of participants and personnel; we judged these at unclear risk of bias (<a href="./references#CD014915-bbs2-0004" title="HardyJ , GreerR , HugegettG , KearneyA , GurgenicT , GoodP . Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). Journal of Clinical Oncology2023;41(7):1444-52. [DOI: 10.1200/JCO.22.]">Hardy 2023</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>; <a href="./references#CD014915-bbs2-0008" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal Pain and Symptom Management2014;47:166-73. [DOI: 10.1016/j.jpainsymman.2013.02.018]">Lynch 2014</a>; <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>; <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>). One study was at high risk of bias, as it did not report if nabiximols and placebo were identical in taste (<a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>). </p> <p>No study reported on details of the blinding of the outcome assessor and therefore we judged all studies at unclear risk of detection bias. </p> </section> <section id="CD014915-sec-0069"> <h4 class="title">Incomplete outcome data</h4> <p>Five studies had high risk of attrition bias, which used completer analysis (<a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>; <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>; <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>). There were some concerns for the remaining studies, which used ITT analysis by LOCF. We judged these studies at unclear risk of bias. </p> </section> <section id="CD014915-sec-0070"> <h4 class="title">Selective reporting</h4> <p>We judged reporting bias as low in the nabiximols studies because there was a study protocol (<a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a>; <a href="./references#CD014915-bbs2-0004" title="HardyJ , GreerR , HugegettG , KearneyA , GurgenicT , GoodP . Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). Journal of Clinical Oncology2023;41(7):1444-52. [DOI: 10.1200/JCO.22.]">Hardy 2023</a>; <a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>). The risk of bias was unclear for the remaining studies because they did not publish a study protocol. </p> </section> <section id="CD014915-sec-0071"> <h4 class="title">Other potential sources of bias</h4> <p>Four studies were at high risk of other bias due to significant differences in demographic or clinical variables (or both) at baseline between the study groups (<a href="./references#CD014915-bbs2-0004" title="HardyJ , GreerR , HugegettG , KearneyA , GurgenicT , GoodP . Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). Journal of Clinical Oncology2023;41(7):1444-52. [DOI: 10.1200/JCO.22.]">Hardy 2023</a>; <a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>; <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>). We found group similarity at baseline in the remaining studies, which were at low risk of other bias. </p> </section> </section> <section id="CD014915-sec-0072"> <h3 class="title" id="CD014915-sec-0072">Effects of interventions</h3> <p>See: <a href="./full#CD014915-tbl-0001"><b>Summary of findings 1</b> Cannabis‐based medicines compared with placebo medication for cancer pain</a> </p> <p>In total, we analysed 14 studies with 20 treatment arms involving 1823 participants. See <a href="./full#CD014915-tbl-0001">summary of findings Table 1</a> for the main comparison. </p> <section id="CD014915-sec-0073"> <h4 class="title">Cannabis‐based medicines as add‐on for opioid refractory cancer pain</h4> <section id="CD014915-sec-0074"> <h5 class="title">Studies with a parallel design</h5> <p>We found four studies with seven study arms including 1334 participants that used a parallel design for nabiximols in participants with opioid‐refractory cancer pain. We report the meta‐analyses below. </p> <section id="CD014915-sec-0075"> <h6 class="title">Primary outcomes</h6> <section id="CD014915-sec-0076"> <p><b>Proportion of participants reporting no worse than mild pain by 14 days after start of treatment</b></p> <p>No study assessed this outcome.</p> </section> <section id="CD014915-sec-0077"> <p><b>Patient Global Impression of Change of much improved or very much improved</b></p> <p>We analysed three studies with five treatment arms. A total of 179/561 (31.9%) participants in the nabiximols and 100/434 (23.0%) participants in the placebo group reported being much or very much improved (RD 0.06, 95% CI 0.01 to 0.12; P = 0.03; I² = 0%; NNTB 16, 95% CI 8 to 100; <a href="./references#CD014915-fig-0004" title="">Analysis 1.1</a>). According to the predefined categories, there was no clinically relevant benefit by nabiximols. We judged the certainty of evidence as moderate, downgraded one level due to limitations of study design (one study was at high risk of bias). </p> </section> <section id="CD014915-sec-0078"> <p><b>Withdrawals due to adverse events</b></p> <p>We analysed four studies with seven treatment arms and 1332 participants. We found 148/785 (18.6%) participants in the nabiximols and 85/547 (15.5%) participants in the placebo group dropped out due to adverse events (RD 0.04, 95% CI 0 to 0.08; P = 0.04; I² = 0%; NNTH 25, 95% CI 12 to indefinite; <a href="./references#CD014915-fig-0005" title="">Analysis 1.2</a>). According to the predefined categories, there was no clinically relevant harm. We judged the certainty of evidence as moderate, downgraded one level due to limitations of study design (two studies were at high risk of bias). </p> </section> </section> <section id="CD014915-sec-0079"> <h6 class="title">Secondary outcomes</h6> <section id="CD014915-sec-0080"> <p><b>Combined responder</b></p> <p>No study assessed this outcome.</p> </section> <section id="CD014915-sec-0081"> <p><b>Number of participants who reported pain relief of 30% or greater</b></p> <p>We analysed four studies with seven treatment arms and 1332 participants. We found 217/785 (26.8%) participants receiving nabiximols and 145/547 (26.5%) participants in the placebo group reported pain relief of 30% or greater (RD 0.02, 95% CI −0.03 to 0.07; P = 0.51; I² = 0%; <a href="./references#CD014915-fig-0006" title="">Analysis 1.3</a>). We judged the certainty of evidence as moderate, downgraded one level due to limitations of study design (two studies at high risk of bias). </p> </section> <section id="CD014915-sec-0082"> <p><b>Number of participants who reported pain relief of 50% or greater</b></p> <p>We analysed four studies with seven treatment arms and 1333 participants. We found 104/786 (13.2%) participants receiving nabiximols and 50/547 (9.1%) participants in the placebo group reported pain relief of 50% or greater (RD 0.01, 95% CI −0.02 to 0.05; P = 0.38; I² = 1%; <a href="./references#CD014915-fig-0007" title="">Analysis 1.4</a>). We judged the certainty of evidence as moderate, downgraded one level due to limitations of study design (two studies at high risk of bias). </p> </section> <section id="CD014915-sec-0083"> <p><b>Mean pain intensity</b></p> <p>We analysed four studies with seven treatment arms and 1315 participants. There was no evidence of a difference in mean pain intensity on a 0 to 10 scale (MD −0.19, 95% CI −0.40 to 0.02; P = 0.08, I² = 21%; <a href="./references#CD014915-fig-0008" title="">Analysis 1.5</a>). We judged the certainty of evidence as moderate, downgraded one level due to limitations of study design (two studies at high risk of bias). </p> </section> <section id="CD014915-sec-0084"> <p><b>Sleep problems</b></p> <p>We analysed four studies with seven treatment arms and 1314 participants. We found no benefit of nabiximols for improving sleep (SMD −0.06, 95% CI −0.19 to 0.06; P = 0.31, I² = 11%; <a href="./references#CD014915-fig-0009" title="">Analysis 1.6</a>). We judged the certainty of evidence as moderate, downgraded one level due to limitations of study design (two studies at high risk of bias). </p> </section> <section id="CD014915-sec-0085"> <p><b>Depression</b></p> <p>In one study including 360 participants, we found no difference between placebo and the low‐dose THC/CBD group (P = 0.48), the medium‐dose THC/CBD group (P = 0.08) and the high‐dose THC/CBD group (P = 0.15) on the Montgomery Åsberg Depression Rating Scale (<a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>). We judged the certainty of evidence as low, downgraded two levels due to limitations of study design (two studies at high risk of bias), and imprecision of results (only one study analysed). </p> </section> <section id="CD014915-sec-0086"> <p><b>Anxiety</b></p> <p>No studies assessed anxiety.</p> </section> <section id="CD014915-sec-0087"> <p><b>Daily maintenance opioid dosage (mg morphine equivalent)</b></p> <p>We analysed three studies with four treatment arms and 970 participants. We found no difference in opioid dose between groups (SMD 0.08, 95% CI −0.10 to 0.27; P = 0.38, I² = 43%; <a href="./references#CD014915-fig-0010" title="">Analysis 1.7</a>). We judged the certainty of evidence as low, downgraded two levels due to limitations of study design (two studies at high risk of bias), and imprecision of results (CIs included zero). <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a> reported that there were no differences between the three dosages arms of THC and CBD (P values not reported). </p> </section> <section id="CD014915-sec-0088"> <p><b>Daily breakthrough opioid dosage (mg morphine equivalent)</b></p> <p>We analysed three studies with four treatment arms and 957 participants. We found no difference between groups (SMD −0.08, 95% CI −0.23 to 0.07; P = 0.29, I² = 19%; <a href="./references#CD014915-fig-0011" title="">Analysis 1.8</a>). <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a> reported that there was no difference between the three dosages arms of THC and CBD (P values not reported). We judged the certainty of evidence as moderate, downgraded one level due to limitations of study design (two studies at high risk of bias). </p> </section> <section id="CD014915-sec-0089"> <p><b>Number of participants dropping out due to lack of efficacy</b></p> <p>No study assessed this outcome.</p> </section> <section id="CD014915-sec-0090"> <p><b>All central nervous system adverse events</b></p> <p>We analysed four studies with seven treatment arms and 1331 participants. We found 202/785 (25.7%) participants receiving nabiximols and 57/546 (10.4%) participants in the placebo group reported nervous system disorders adverse events (RD 0.11, 95% CI 0.05 to 0.17; P &lt; 0.001; I² = 43%; NNTH 9, 95% CI 6 to 25; <a href="./references#CD014915-fig-0012" title="">Analysis 1.9</a>). According to the predefined categories there was a clinically relevant harm by nabiximols. We judged the certainty of evidence as moderate, downgraded one level due to limitations of study design (two studies at high risk of bias). </p> </section> <section id="CD014915-sec-0091"> <p><b>All psychiatric adverse events</b></p> <p>We analysed four studies with seven treatment arms and 1331 participants. We found 75/785 (9.6%) participants receiving nabiximols and 17/546 (3.1%) participants in the placebo group reported psychiatric disorders adverse events (RD 0.01, 95% CI −0.01 to 0.04; P = 0.24; I² = 35%; <a href="./references#CD014915-fig-0013" title="">Analysis 1.10</a>). We judged the certainty of evidence as moderate, downgraded one level due to limitations of study design (two studies at high risk of bias). </p> </section> <section id="CD014915-sec-0092"> <p><b>Participants experiencing any serious adverse event</b></p> <p>We analysed four studies with seven treatment arms and 1330 participants. We found 187/784 (23.9%) participants receiving nabiximols and 116/546 (21.2%) participants in the placebo group reported serious adverse events (RD 0.02, 95% CI −0.03 to 0.07; P = 0.43; I² = 9%; <a href="./references#CD014915-fig-0014" title="">Analysis 1.11</a>). We judged the certainty of evidence as moderate, downgraded one level due to limitations of study design (two studies at high risk of bias). </p> </section> </section> </section> <section id="CD014915-sec-0093"> <h5 class="title">Studies with a withdrawal design</h5> <p>We found one study with 206 participants that used a withdrawal design (<a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a>). We could not meta‐analyse the results, so we describe the double‐blind period only below. </p> <section id="CD014915-sec-0094"> <h6 class="title">Primary outcomes</h6> <section id="CD014915-sec-0095"> <p><b>Proportion of participants reporting no worse than mild pain 14 days after start of treatment</b></p> <p>The study did not assess this outcome.</p> </section> <section id="CD014915-sec-0096"> <p><b>Patient Global Impression of Change of much improved or very much improved</b></p> <p>There was no evidence of a difference on the mean PGIC (0.33, 95% CI –0.35 to 0.41; P = 0.41). We judged the certainty of evidence as moderate, downgraded one level due to imprecision of results (only one study available). </p> </section> <section id="CD014915-sec-0097"> <p><b>Withdrawals due to adverse event</b></p> <p>We found 21/103 of participants receiving nabiximols and 13/103 in placebo group withdrew due to adverse events (P = 0.05). We judged the certainty of evidence as low, downgraded one level to low due to imprecision of results (only one study available). </p> </section> </section> <section id="CD014915-sec-0098"> <h6 class="title">Secondary outcomes</h6> <section id="CD014915-sec-0099"> <p><b>Combined responder</b></p> <p>The study did not assess this outcome.</p> </section> <section id="CD014915-sec-0100"> <p><b>Number of participants who reported pain relief of 30% or greater</b></p> <p>The study did not assess this outcome.</p> </section> <section id="CD014915-sec-0101"> <p><b>Number of participants who reported pain relief of 50% or greater</b></p> <p>The study did not assess this outcome.</p> </section> <section id="CD014915-sec-0102"> <p><b>Mean pain intensity</b></p> <p>There was no evidence of a difference in mean pain intensity (MD −0.02, 95% CI –0.42 to 0.38; P = 0.92). We judged the certainty of evidence as moderate, downgraded one level due to and imprecision of results (only one study available). </p> </section> <section id="CD014915-sec-0103"> <p><b>Sleep problems</b></p> <p>There was no evidence of a difference in sleep problems (MD 0.06, 95 CI –0.28 to 0.39; P = 0.73). We judged the certainty of evidence as moderate, downgraded one level due to imprecision of results (only one study available). </p> </section> <section id="CD014915-sec-0104"> <p><b>Depression</b></p> <p>The study did not assess this outcome.</p> </section> <section id="CD014915-sec-0105"> <p><b>Anxiety</b></p> <p>The study did not assess this outcome.</p> </section> <section id="CD014915-sec-0106"> <p><b>Daily maintenance opioid dosage (mg morphine equivalent)</b></p> <p>There was no evidence of a difference in daily maintenance opioid dosage (MD –8.93, 95% CI –19.69 to 1.84; P = 0.10). We judged the certainty of evidence as low, downgraded one level due to imprecision of results (only one study available). </p> </section> <section id="CD014915-sec-0107"> <p><b>Daily breakthrough opioid dosage (mg morphine equivalent)</b></p> <p>There was no evidence of a difference in daily breakthrough opioid dosage (MD 1.81, 95% CI –10.34 to 13.69; P = 0.77). We judged the certainty of evidence as moderate, downgraded one level due to imprecision of results (only one study available). </p> </section> <section id="CD014915-sec-0108"> <p><b>Number of participants dropping out due to lack of efficacy</b></p> <p>One participant in each group withdraw due to lack of efficacy. We judged the certainty of evidence as moderate, downgraded one level due to imprecision of results (low number of events). </p> </section> <section id="CD014915-sec-0109"> <p><b>All central nervous system adverse events</b></p> <p>Six participants in the nabiximols and one in the placebo group reported dizziness or somnolence. We judged the certainty of evidence as moderate, downgraded one level due to imprecision of results (only one study available). </p> </section> <section id="CD014915-sec-0110"> <p><b>All psychiatric adverse events</b></p> <p>There were no treatment‐emergent suicidal ideations or behaviour in either group. We judged the certainty of evidence as moderate, downgraded one level due to imprecision of results (low number of events). </p> </section> <section id="CD014915-sec-0111"> <p><b>Participants experiencing any serious adverse event</b></p> <p>There were treatment‐related serious adverse events in 33/103 of nabiximols‐treated and 16/103 of placebo‐treated participants (P = 0.13). We judged the certainty of evidence as moderate, downgraded one level due to imprecision of results (low number of events). </p> </section> </section> </section> </section> <section id="CD014915-sec-0112"> <h4 class="title">Nabiximols for cancer therapy‐induced neuropathic pain</h4> <p>We found one study with 16 participants that delivered nabiximols for cancer therapy‐induced neuropathic pain (<a href="./references#CD014915-bbs2-0008" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal Pain and Symptom Management2014;47:166-73. [DOI: 10.1016/j.jpainsymman.2013.02.018]">Lynch 2014</a>). This could not be meta‐analysed, so we described the results below. </p> <section id="CD014915-sec-0113"> <h5 class="title">Primary outcomes</h5> <section id="CD014915-sec-0114"> <h6 class="title">Proportion of participants reporting no worse than mild pain by 14 days after start of treatment </h6> <p>The study did not assess this outcome.</p> </section> <section id="CD014915-sec-0115"> <h6 class="title">Patient Global Impression of Change of much improved or very much improved</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD014915-sec-0116"> <h6 class="title">Withdrawals due to adverse event</h6> <p>The study did not report why two participants dropped out.</p> </section> </section> <section id="CD014915-sec-0117"> <h5 class="title">Secondary outcomes</h5> <section id="CD014915-sec-0118"> <h6 class="title">Combined responder</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD014915-sec-0119"> <h6 class="title">Number of participants who reported pain relief of 30% or greater</h6> <p>We found 5/18 participants with nabiximols and 3/18 participants with placebo reported pain relief of 30% or greater (P = 0.16). We judged the certainty of evidence as low, downgraded two levels due to limitations of study design (study with high risk of bias) and imprecision of results (only one study with low number of participants available). </p> </section> <section id="CD014915-sec-0120"> <h6 class="title">Number of participants who reported pain relief of 50% or greater</h6> <p>We found 2/18 participants with nabiximols and 3/18 participants with placebo reported pain relief of 50% or greater (P = 0.47). We judged the certainty of evidence as low, downgraded two levels due to limitations of study design (study with high risk of bias) and imprecision of results (only one study with low number of participants available). </p> </section> <section id="CD014915-sec-0121"> <h6 class="title">Main pain intensity</h6> <p>The mean pretreatment score was 6.75 and was 6.00 in the nabiximols and 6.38 in the placebo group. We judged the certainty of evidence as low, downgraded two levels due to limitations of study design (study with high risk of bias) and imprecision of results (only one study with low number of participants available). </p> </section> <section id="CD014915-sec-0122"> <h6 class="title">Sleep problems</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD014915-sec-0123"> <h6 class="title">Depression</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD014915-sec-0124"> <h6 class="title">Anxiety</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD014915-sec-0125"> <h6 class="title">Daily maintenance opioid dosage (mg morphine equivalent)</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD014915-sec-0126"> <h6 class="title">Daily breakthrough opioid dosage (mg morphine equivalent)</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD014915-sec-0127"> <h6 class="title">Number of participants dropping out due to lack of efficacy</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD014915-sec-0128"> <h6 class="title">All central nervous system adverse events</h6> <p>Nine participants with nabiximols (six dizziness, one confusion, two "foggy brain") and none with placebo reported nervous system adverse events (P = 0.02). We judged the certainty of evidence as low, downgraded two levels due to limitations of study design (study with high risk of bias) and imprecision of results (only one study with low number of participants available). </p> </section> <section id="CD014915-sec-0129"> <h6 class="title">All psychiatric adverse events</h6> <p>Three participants with nabiximols and none with placebo reported on psychiatric disorders adverse events (feeling "stoned", anxiety and panic attack, one each) (P = 0.23). We judged the certainty of evidence as low, downgraded two levels due to limitations of study design (study with high risk of bias) and imprecision of results (only one study with low number of participants available). </p> </section> <section id="CD014915-sec-0130"> <h6 class="title">Participants experiencing any serious adverse event</h6> <p>The study reported "There were no serious medication‐related events."</p> </section> </section> </section> <section id="CD014915-sec-0131"> <h4 class="title">Studies with synthetic tetrahydrocannabinol analogue (nabilone) compared to placebo to improve health‐related quality of life of people undergoing radiation or radiochemotherapy </h4> <p>We found two studies with 89 participants that delivered nabilone to improve health‐related quality of life of people undergoing radiation or radiochemotherapy (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>; <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>). The presentation of the outcomes did not allow quantitative synthesis, so we described the results below. </p> <section id="CD014915-sec-0132"> <h5 class="title">Primary outcomes</h5> <section id="CD014915-sec-0133"> <h6 class="title">Proportion of participants reporting no worse than mild pain by 14 days after start of treatment </h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0134"> <h6 class="title">Patient Global Impression of Change of much improved or very much improved</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0135"> <h6 class="title">Withdrawals due to adverse events</h6> <p>Neither study reported withdrawal due to adverse effects in detail. We judged the certainty of evidence as low, downgraded two levels due to limitations of study design (study with high risk of bias) and imprecision of results (low number of participants). </p> </section> </section> <section id="CD014915-sec-0136"> <h5 class="title">Secondary outcomes</h5> <section id="CD014915-sec-0137"> <h6 class="title">Combined responder</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0138"> <h6 class="title">Number of participants who reported pain relief of 30% or greater</h6> <p>Neither study reported this outcome. We could not use the imputation method because <a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a> did not report baseline pain intensity. By imputation, <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a> reported 7/14 participants in the nabilone and 7/19 participants in the placebo group experienced pain relief of 30% or greater (P = 0.45). We judged the certainty of evidence as low, downgraded two levels due to limitations of study design (one study with high risk of bias) and imprecision of results (low number of participants). </p> </section> <section id="CD014915-sec-0139"> <h6 class="title">Number of participants who reported pain relief of 50% or greater</h6> <p>Neither study reported this outcome. We could not use the imputation method because <a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a> did not report baseline pain intensity. By imputation, <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a> reported 5/14 participants in the nabilone and 5/19 participants in the placebo group experienced pain relief of 50% or greater (P = 0.56). We judged the certainty of evidence as low, downgraded two levels due to limitations of study design (one study with high risk of bias) and imprecision of results (low number of participants). </p> </section> <section id="CD014915-sec-0140"> <h6 class="title">Mean pain intensity</h6> <p><a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a> reported no difference between nabilone and placebo in mean pain intensity (P = 0.61). <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a> reported the change in mean pain intensity score in the nabilone group from baseline to the end of treatment was 13 in the nabilone group and 6.6 in the control group on a 0 to 100 scale. We judged the certainty of evidence as low, downgraded two levels due to limitations of study design (one study with high risk of bias) and imprecision of results (low number of participants). </p> </section> <section id="CD014915-sec-0141"> <h6 class="title">Sleep problems</h6> <p><a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a> reported no difference between nabilone and placebo in sleep problems (P = 0.44). <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a> reported change in mean insomnia score in the nabilone group from baseline to the end of treatment was −40.7 in the nabilone group and −9.9 in the control group on a 0 to 100 scale. We judged the certainty of evidence as low, downgraded two levels due to limitations of study design (one study with high risk of bias) and imprecision of results (low number of participants). </p> </section> <section id="CD014915-sec-0142"> <h6 class="title">Depression</h6> <p><a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a> reported no difference between nabilone and placebo on mood (P = 0.32). <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a> did not assess this outcome. We judged the certainty of evidence as low, downgraded two levels due to limitations of study design (one study with high risk of bias) and imprecision of results (low number of participants). </p> </section> <section id="CD014915-sec-0143"> <h6 class="title">Anxiety</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0144"> <h6 class="title">Daily maintenance opioid dosage (mg morphine equivalent)</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0145"> <h6 class="title">Daily breakthrough opioid dosage (mg morphine equivalent)</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0146"> <h6 class="title">Number of participants dropping out due to lack of efficacy</h6> <p>Neither study reported withdrawals due to lack of efficacy in detail. We judged the certainty of evidence as low, downgraded two levels due to limitations of study design (one study with high risk of bias) and imprecision of results (low number of participants). </p> </section> <section id="CD014915-sec-0147"> <h6 class="title">All central nervous system adverse events</h6> <p><a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a> reported that there was no difference between nabilone and placebo in the prevalence of drowsiness (P = 0.32). <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a> did not assess this outcome. We judged the certainty of evidence as low, downgraded two levels due to limitations of study design (one study with high risk of bias) and imprecision of results (low number of participants). </p> </section> <section id="CD014915-sec-0148"> <h6 class="title">All psychiatric adverse events</h6> <p><a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a> reported that there was no difference between nabilone and placebo in the prevalence of anxiety (P = 0.91). <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a> did not assess this outcome. We judged the certainty of evidence as low, downgraded two levels due to limitations of study design (one study with high risk of bias) and imprecision of results (low number of participants). </p> </section> <section id="CD014915-sec-0149"> <h6 class="title">Participants experiencing any serious adverse event</h6> <p>Neither study explicitly mentioned serious adverse events.</p> </section> </section> </section> <section id="CD014915-sec-0150"> <h4 class="title">Experimental (single dosage) studies to reduce cancer pain: synthetic THC analogue versus placebo </h4> <p>We found five studies with 126 participants that delivered a single dosage of a synthetic THC analogue (<a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>; <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>; <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>). </p> <section id="CD014915-sec-0151"> <h5 class="title">Primary outcomes</h5> <section id="CD014915-sec-0152"> <h6 class="title">Proportion of participants reporting no worse than mild pain by 14 days after start of treatment </h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0153"> <h6 class="title">Patient Global Impression of Change of much improved or very much improved</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0154"> <h6 class="title">Withdrawals due to adverse events</h6> <p>The studies did not assess this outcome.</p> </section> </section> <section id="CD014915-sec-0155"> <h5 class="title">Secondary outcomes</h5> <section id="CD014915-sec-0156"> <h6 class="title">Combined responder</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0157"> <h6 class="title">Number of participants who reported pain relief of 30% or greater</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0158"> <h6 class="title">Number of participants who reported pain relief of 50% or greater</h6> <p><a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a> reported that 23% of participants with 4 mg of a synthetic THC analogue, 40% of participants with 2 mg of a synthetic THC analogue and 43% of participants with placebo reported pain relief of 50% or greater. We judged the certainty of evidence as low, downgraded two levels due to limitations of study design (all studies with high risk of bias) and imprecision of results (low number of participants). </p> </section> <section id="CD014915-sec-0159"> <h6 class="title">Mean pain intensity</h6> <p>We analysed three studies with four treatment arms and 301 participants. There was a difference in mean pain intensity in favour of THC analogue (SMD of pain reduction −0.98, 95% CI −1.36 to −0.60; P &lt; 0.001, I² = 54%; <a href="./references#CD014915-fig-0015" title="">Analysis 2.1</a>). The effect size was large according to Cohen's categories. The criterion of a clinically relevant effect was met. We judged the certainty of evidence as low, downgraded two levels due to limitations of study design (all studies with high risk of bias) and inconsistency (high heterogeneity). <a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a> stated that "reductions of pain intensity occurred in a larger proportion of patients than pain relief, but the reductions were small and clearly without clinical significance." A total of 19/35 participants with 2 mg synthetic THC analogue, 20/35 participants with 4 mg synthetic THC analogue and 25/35 participants with placebo reported a pain reduction. </p> </section> <section id="CD014915-sec-0160"> <h6 class="title">Sleep problems</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0161"> <h6 class="title">Depression</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0162"> <h6 class="title">Anxiety</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0163"> <h6 class="title">Daily maintenance opioid dosage (mg morphine equivalent)</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0164"> <h6 class="title">Daily breakthrough opioid dosage (mg morphine equivalent)</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0165"> <h6 class="title">Number of participants dropping out due to lack of efficacy</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0166"> <h6 class="title">All central nervous system adverse events</h6> <p><a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a> did not report nervous system adverse events in the placebo group. <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a> reported 94% of participants with THC 20 mg, 71% of participants with THC 10 mg and 29% of participants with placebo reported sedation. <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a> reported 14 nervous system adverse events (drowsiness, dizziness) with 5 mg, 19 with 10 mg, 26 with 15 mg, and 36 with 20 mg synthetic THC analogue, and 21 with placebo. <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a> and <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a> pooled the data of both studies and reported that 40% of participants reported drowsiness with synthetic THC analogue and 21% of participants reported drowsiness with placebo. We judged the certainty of evidence as low, downgraded two levels due to limitations of study design (all studies with high risk of bias) and imprecision of results (low number of participants). </p> </section> <section id="CD014915-sec-0167"> <h6 class="title">All psychiatric adverse events</h6> <p><a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a> reported that "psychiatric interview, failed to reveal any consistent changes which could be ascribed to any drug or to the test period as a whole." <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a> reported 62 psychiatric adverse events (mental clouding, disorientation thought, slurred speech) in the 20 mg synthetic THC analogue group, 32 in the 10 mg synthetic THC analogue group and 15 in the placebo group. <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a> reported 17 psychiatric adverse events (slurred speech, blurred vision, mental clouding, dreaminess, disconnected thought, euphoria, visual hallucinations) in the 5 mg, 19 in the 10 mg, 33 in the 15 mg and 37 in the 20 mg synthetic THC analogue groups and five in the placebo group. <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a> and <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a> pooled the data of both studies and reported there was no euphoria reported by participants with synthetic THC analogue and placebo. We judged the certainty of evidence as low, downgraded two levels due to limitations of study design (all studies with high risk of bias) and imprecision of results (low number of participants). </p> </section> <section id="CD014915-sec-0168"> <h6 class="title">Participants experiencing any serious adverse event</h6> <p>The studies did not assess this outcome.</p> </section> </section> </section> <section id="CD014915-sec-0169"> <h4 class="title">Experimental (single dosage) studies to reduce cancer pain: synthetic THC analogue versus codeine </h4> <p>We found four studies with 116 participants which compared a single dose of a synthetic THC analogue with a single dose of codeine<i>.</i> </p> <section id="CD014915-sec-0170"> <h5 class="title">Primary outcomes</h5> <section id="CD014915-sec-0171"> <h6 class="title">Proportion of participants reporting no worse than mild pain by 14 days after start of treatment </h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0172"> <h6 class="title">Patient Global Impression of Change of much improved or very much improved</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0173"> <h6 class="title">Withdrawals due to adverse events</h6> <p>The studies did not assess this outcome.</p> </section> </section> <section id="CD014915-sec-0174"> <h5 class="title">Secondary outcomes</h5> <section id="CD014915-sec-0175"> <h6 class="title">Combined responder</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0176"> <h6 class="title">Number of participants who reported pain relief of 30% or greater</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0177"> <h6 class="title">Number of participants who reported pain relief of 50% or greater</h6> <p><a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a> reported that 23% of participants with 4 mg of a synthetic THC analogue, 40% of participants with 2 mg of a synthetic THC analogue, 57% of participants with codeine 120 mg and 49% of participants with codeine 60 mg reported pain relief of 50% or greater. We judged the certainty of evidence as low, downgraded two levels due to limitations of study design (all studies with high risk of bias) and imprecision of results (low number of participants). </p> </section> <section id="CD014915-sec-0178"> <h6 class="title">Mean pain intensity</h6> <p>We analysed two studies with three treatment arms and 194 participants. There was no evidence of a difference in pain intensity (SMD 0.03, 95% CI −0.25 to 0.32; P = 0.82, I² = 0%; <a href="./references#CD014915-fig-0016" title="">Analysis 3.1</a>). We judged the certainty of evidence as low, downgraded two levels due to limitations of study design (both studies with high risk of bias) and imprecision of results (CIs included zero). In <a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>, we found 19/35 participants receiving synthetic THC analogue 2 mg, 20/35 participants receiving synthetic THC analogue 4 mg, 25/35 participants receiving codeine 60 mg and 31/35 participants receiving codeine 120 mg reported a pain reduction. </p> </section> <section id="CD014915-sec-0179"> <h6 class="title">Sleep problems</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0180"> <h6 class="title">Depression</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0181"> <h6 class="title">Anxiety</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0182"> <h6 class="title">Daily maintenance opioid dosage (mg morphine equivalent)</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0183"> <h6 class="title">Daily breakthrough opioid dosage (mg morphine equivalent)</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0184"> <h6 class="title">Number of participants dropping out due to lack of efficacy</h6> <p>The studies did not assess this outcome.</p> </section> <section id="CD014915-sec-0185"> <h6 class="title">All central nervous system adverse events</h6> <p><a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a> reported that the sedation induced by synthetic THC analogue in doses of 2 mg and 4 mg was of the same order as that induced by the two doses of codeine, "although this was not marked for either drug." <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a> reported that 94% of participants with THC 20 mg, 71% of participants with THC 10 mg, 47% of participants with codeine 60 mg and 50% of participants with codeine 120 mg reported sedation. <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a> and <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a> pooled the data of both studies and reported that 40% of participants with synthetic THC analogue and 44% of participants treated with codeine reported drowsiness. We judged the certainty of evidence as low, downgraded two levels due to limitations of study design (all studies with high risk of bias) and imprecision of results (low number of participants). </p> </section> <section id="CD014915-sec-0186"> <h6 class="title">All psychiatric adverse events</h6> <p><a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a> reported that "psychiatric interview, failed to reveal any consistent changes which could be ascribed to any drug or to the test period as a whole". <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a> reported 62 psychiatric adverse events (mental clouding, disorientation thought, slurred speech) in the 20 mg, 32 in the 10 mg, 11 in the codeine 60 mg and seven in the codeine 120 mg group. <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a> and <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a> pooled the data of both studies; participants reported no euphoria with synthetic THC analogue. We judged the certainty of evidence as low, downgraded two levels due to limitations of study design (all studies with high risk of bias) and imprecision of results (low number of participants). </p> </section> <section id="CD014915-sec-0187"> <h6 class="title">Participants experiencing any serious adverse event</h6> <p>The studies did not assess this outcome.</p> </section> </section> </section> <section id="CD014915-sec-0188"> <h4 class="title">Cannabidiol added to specialist palliative care to reduce pain in advanced cancer</h4> <p>We found one study with 142 participants (<a href="./references#CD014915-bbs2-0004" title="HardyJ , GreerR , HugegettG , KearneyA , GurgenicT , GoodP . Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). Journal of Clinical Oncology2023;41(7):1444-52. [DOI: 10.1200/JCO.22.]">Hardy 2023</a>). We report the outcomes at day 28. </p> <section id="CD014915-sec-0189"> <h5 class="title">Primary outcomes</h5> <section id="CD014915-sec-0190"> <h6 class="title">Proportion of participants reporting no worse than mild pain by 14 days after start of treatment </h6> <p>The study did not assess this outcome.</p> </section> <section id="CD014915-sec-0191"> <h6 class="title">Patient Global Impression of Change of much improved or very much improved</h6> <p>About 70% of participants in the CBD group and 64% in the placebo group reported feeling better or much better. </p> </section> <section id="CD014915-sec-0192"> <h6 class="title">Withdrawals due to adverse events</h6> <p>A total of 10/70 participants withdrew with CBD and 8/72 participants withdrew with placebo. </p> </section> </section> <section id="CD014915-sec-0193"> <h5 class="title">Secondary outcomes</h5> <section id="CD014915-sec-0194"> <h6 class="title">Combined responder</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD014915-sec-0195"> <h6 class="title">Number of participants who reported pain relief of 30% or greater</h6> <p>A total of 26/70 in the CBD group and 29/72 in the placebo group reported pain relief of 30% or greater (calculated by imputation method). </p> </section> <section id="CD014915-sec-0196"> <h6 class="title">Number of participants who reported pain relief of 50% or greater</h6> <p>A total of 19/70 in the CBD group and 20/72 in the placebo group reported pain relief of 50% or greater (calculated by imputation method). </p> </section> <section id="CD014915-sec-0197"> <h6 class="title">Mean pain intensity</h6> <p>In the CBD group, baseline pain score (VAS 0 to 100) was 40.34 (SD 26.26) and at 28 days was 37.80 (SD 28.14). In the placebo group, baseline pain score (VAS 0 to 100) was 50.94 (SD 30.20) and at 28 days was 43.56 (SD 30.54). </p> </section> <section id="CD014915-sec-0198"> <h6 class="title">Sleep problems</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD014915-sec-0199"> <h6 class="title">Depression</h6> <p>The mean change in depression in the CBD group was −0.50 (SD 0.46) and in the placebo group was −0.63 (SD 0.405). </p> </section> <section id="CD014915-sec-0200"> <h6 class="title">Anxiety</h6> <p>The mean change in the CBD group was −1.10 (SD 0.44) and in the placebo group was −0.79 (SD 0.43). </p> </section> <section id="CD014915-sec-0201"> <h6 class="title">Daily opioid dosage (mg morphine equivalent)</h6> <p>The study did not make a distinction between maintenance and breakthrough opioid doses. At day 28, 3/42 (7.1%) participants in the CBD group and 6/4 (13.6%) participants in the placebo group had a morphine dose reduction from baseline; 20/42 (47.6%) participants in the CBD group and 21/42 (50%) participants in the placebo group had no change; and 18/42 (42.9%) participants in the CBD group and 16/42 (38.1%) participants in the placebo group had an increase in total opioid dose. </p> </section> <section id="CD014915-sec-0202"> <h6 class="title">Number of participants dropping out due to lack of efficacy</h6> <p>The study did not assess this outcome.</p> </section> <section id="CD014915-sec-0203"> <h6 class="title">All central nervous system adverse events</h6> <p>A total of 30/66 (45%) participants in the CBD group and 21/68 (31%) participants in the placebo group reported new or worse days with somnolence; 16/66 (24%) participants in the CBD group and 14/68 (11%) participants in the placebo group reported new or worse days with dizziness; and 9/70 (12.8%) participants in the CBD group and 7/72 (9.7%) participants in the placebo group reported new or worse days with fatigue. </p> </section> <section id="CD014915-sec-0204"> <h6 class="title">All psychiatric adverse events</h6> <p>A total of 3/70 (4.3%) participants in the CBD group and 1/72 (1.4%) participants in the placebo group reported new or worse days with anxiety. </p> </section> <section id="CD014915-sec-0205"> <h6 class="title">Participants experiencing any serious adverse event</h6> <p>There were eight serious adverse events resulting in hospitalisations (five in the CBD group and three in the placebo group). </p> </section> </section> </section> <section id="CD014915-sec-0206"> <h4 class="title">Subgroup analysis</h4> <p>We conducted a subgroup analysis comparing the effects of lower dosages of synthetic THC analogue (5 mg or 10 mg) versus placebo (four studies with 193 participants) compared to higher dosages of synthetic THC analogue (15 mg or 20 mg) versus placebo (two studies with 108 participants) on mean pain intensity. The P value for the subgroup comparison was 0.16 (see <a href="./references#CD014915-fig-0015" title="">Analysis 2.1</a>). </p> <p>We conducted a subgroup analysis comparing the effects of lower dosages of synthetic THC analogue (4 mg or 10 mg) versus codeine 50 mg or 60 mg (two studies with 126 participants) compared to higher dosages of synthetic THC analogue (20 mg) versus codeine 120 mg. The P value of subgroup comparison was 0.51 (see <a href="./references#CD014915-fig-0016" title="">Analysis 3.1</a>). </p> <p>We did not perform the other predefined subgroup analyses because most subgroups included only one study or treatment arm. </p> </section> <section id="CD014915-sec-0207"> <h4 class="title">Sensitivity analysis</h4> <p>By removing one study with one treatment arm with imputed rates for pain relief of 30% or greater, the RD of the remaining study with two study arms was 0.03 (95% CI −0.03 to 0.09; P = 0.31). </p> </section> <section id="CD014915-sec-0208"> <h4 class="title">Publication bias</h4> <p><a href="./references#CD014915-fig-0004" title="">Analysis 1.1</a> for PGIC much or very much improved had an NNTB of 16. This precluded any sensitivity analysis for publication bias as the NNTB of 16 was already higher than the preset utility boundary of an NNTB of 10. Increasing the preset boundary to an NNTB of 20 would mean that results from 249 participants in zero treatment effect trials would be required to that higher level. That is about the size of one of the larger trials included in the analysis. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD014915-sec-0209" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD014915-sec-0209"></div> <section id="CD014915-sec-0210"> <h3 class="title" id="CD014915-sec-0210">Summary of main results</h3> <p>We identified five RCTs delivering oromucosal nabiximols or THC to 1539 participants with moderate and severe pain despite opioid therapy (<a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a>; <a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>). The double‐blind periods of the RCTs ranged between two and five weeks. We found four studies that used a parallel design and included 1333 participants that could be included in a meta‐analysis (<a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>). The certainty of evidence was moderate for all comparisons except one, which was low. Nabiximols and THC did not differ from placebo in reducing pain, sleep problems, and opioid maintenance and breakthrough dosages. There was no clinically relevant benefit of nabiximols for the number of participants who reported that they were much or very much improved (NNTB 16, 95% CI 6 to 100). There was no difference between nabiximols and THC versus placebo with regards to the dropout rates due to adverse events and to the frequency of psychiatric disorders as adverse events. There was a clinically relevant harm by nabiximols and THC in the frequency of nervous system adverse events compared to placebo (NNTH 9, 95% CI 6 to 20). </p> <p>We found low‐certainty evidence for two RCTs of eight weeks' duration that delivered nabilone (compared to placebo) in 89 participants (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>; <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>). We found that nabilone did not reduce pain associated with chemotherapy or radiochemotherapy in people with head and neck cancer and non‐small cell lung cancer. </p> <p>We found low‐certainty evidence across five single‐dose RCTs with 126 participants that synthetic THC analogue was superior to placebo and not superior to codeine in reducing moderate‐to‐severe cancer pain after cessation of previous analgesic treatment for three to 4.5 hours (<a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>; <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>; <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>). </p> </section> <section id="CD014915-sec-0211"> <h3 class="title" id="CD014915-sec-0211">Overall completeness and applicability of evidence</h3> <p>The evidence for all types of CbMs and medical cannabis is not complete because we did not analyse studies with medical cannabis only. The ongoing studies might change the findings and conclusions of our review (<a href="./references#CD014915-bbs2-0016" title="ACTRN12619001534178. A phase I/II double-blind, randomised controlled trial assessing effect of medicinal cannabis on quality of life and symptom control in advanced cancer. anzctr.org.au/ACTRN12619001534178.aspx (first received 30 September 2019). [anzctr.org.au/ACTRN12619001534178.aspx]">ACTRN12619001534178</a>; <a href="./references#CD014915-bbs2-0017" title="ACTRN12621001302842. NanaBis™ an oro-buccal administered delta9-tetrahydrocannabinol (d9-THC) and cannabidiol (CBD) medicine for the management of chronic pain from metastatic bone cancer. anzctr.org.au/ACTRN12621001302842.aspx (first received 14 April 2021). [anzctr.org.au/ACTRN12621001302842.aspx]">ACTRN12621001302842</a>; <a href="./references#CD014915-bbs2-0018" title="EudraCT 001382-32. A double-blind, randomized phase 1/2 study to assess the efficacy and safety of BCT-521 versus placebo for pain associated with cancer inpatients already receiving standard of care treatment with opioids. www.clinicaltrialsregister.eu/ctr-search/trial/2019-001382-32/PL/ (first received 1 August 2019). ">EudraCT 001382‐32</a>; <a href="./references#CD014915-bbs2-0019" title="HardyJ , HaywoodA , GognaG , MartinJ , YatesP , GreerR , et al. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Trials2020;21:611. [DOI: 10.1186/s13063-020-04541-6]">Hardy 2020</a>; <a href="./references#CD014915-bbs2-0020" title="NCT04042545. Safety and efficacy of inhaled cannabis for the uncontrolled pain relief in patients with advanced cancer (PLENITUDE). clinicaltrials.gov/ct2/show/NCT04042545 (first received 2 August 2019). [clinicaltrials.gov/ct2/show/NCT04042545]">NCT04042545</a>). The usefulness of the available evidence is limited because the quality of studies was overall poor by current standards. The results of the studies analysed can be mainly applied to routine clinical care because the participants included in the clinical studies were largely representative for people with cancer in routine clinical care. However, the studies with nabiximols excluded studies with advanced hepatic and renal failure (<a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a>; <a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>). </p> </section> <section id="CD014915-sec-0212"> <h3 class="title" id="CD014915-sec-0212">Quality of the evidence</h3> <p>We found the evidence for the outcomes of the studies with synthetic THC analogues to be low quality because of limitations of study design and imprecision (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>; <a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>; <a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>; <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>; <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>), and the outcomes of the studies with nabiximols to be moderate quality because of limitations of study design (<a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>). Our confidence in the effect estimates is limited; the true effect may be substantially different from the estimate of the effect. </p> <p>In addition, the studies with synthetic THC analogues might have overestimated the effect size due to their small sample size (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>; <a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>; <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>; <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>; <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>). </p> <p>Six studies used a cross‐over design (<a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>; <a href="./references#CD014915-bbs2-0008" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal Pain and Symptom Management2014;47:166-73. [DOI: 10.1016/j.jpainsymman.2013.02.018]">Lynch 2014</a>; <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>; <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>), which has methodological issues that could lead to bias (<a href="./references#CD014915-bbs2-0034" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology2002;31:140-9. [DOI: 10.1093/ije/31.1.140]">Elbourne 2002</a>). </p> <p>The experimental studies with synthetic THC analogue were single‐dose studies (<a href="./references#CD014915-bbs2-0005" title="JochimsenPR , LawtonRL , VerSteegK , Noyes R Jr. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clinical Pharmacology &amp; Therapeutics1978;24:223-7. [DOI: 10.1002/cpt1978242223]">Jochimsen 1978</a>; <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>; <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>). We do not know if the effects on pain relief can be maintained. Another concern is the short study duration of the nabiximols and dronabinol studies (<a href="./references#CD014915-bbs2-0001" title="CôtéM , TrudelM , WangC , FortinA . Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: a randomized double-blind placebo-controlled trial. Annals of Otology, Rhinology, and Laryngology2016;125(4):317-24. ">Côté 2016</a>; <a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a>; <a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>; <a href="./references#CD014915-bbs2-0008" title="LynchME , Cesar-RittenbergP , HohmannAG . A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. Journal Pain and Symptom Management2014;47:166-73. [DOI: 10.1016/j.jpainsymman.2013.02.018]">Lynch 2014</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>; <a href="./references#CD014915-bbs2-0014" title="TurcottJG , Del Rocío Guillen NúñezM , Flores-EstradaD , Oñate-OcañaLF , Zatarain-BarrónZL , BarrónF , et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer2018;26(9):3029-38. [DOI: 10.1007/s00520-018-4154-9]">Turcott 2018</a>) and CBD study (<a href="./references#CD014915-bbs2-0004" title="HardyJ , GreerR , HugegettG , KearneyA , GurgenicT , GoodP . Phase IIb randomized, placebo-controlled, dose-escalating, double-blind study of cannabidiol oil for the relief of symptoms in advanced cancer (MedCan1-CBD). Journal of Clinical Oncology2023;41(7):1444-52. [DOI: 10.1200/JCO.22.]">Hardy 2023</a>), with no intermediate (12 to 26 weeks) or long‐term (greater than 26 weeks) randomised study. However, long‐term studies are difficult to conduct in people with advanced cancer because of the limited life expectancy. </p> <p>There are different types of cancer pain (bone, neuropathic, visceral, somatic). Although the nabiximols studies reported the percentages of these categories of cancer pain in the baseline characteristics (<a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a>; <a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>), no study has conducted subgroup analyses according to these cancer pain characteristics. </p> </section> <section id="CD014915-sec-0213"> <h3 class="title" id="CD014915-sec-0213">Potential biases in the review process</h3> <p>We conducted a broad search for studies and believe that it is unlikely that significant amounts of relevant data have been overlooked. We cannot exclude the possibility that early studies including synthetic THC analogues have not been published before registration of a study protocol was required for approval by ethical committees or drug agencies. </p> <p>We did not analyse other relevant symptoms associated with cancer pain such as fatigue and did not analyse other relevant adverse effects of CbMs such as gastrointestinal disorders. </p> <p>We had to estimate some missing SDs from P values. We calculated most 50% responder rates of the nabiximols studies using imputation methods. </p> <p>All studies used statistical methods (LOCF, completer analysis) that bias results towards exaggerating the efficacy of the medication. </p> <p>The influence of allowed co‐interventions (e.g. rescue medication) on positive effects and adverse events was unclear because type and dosage of co‐interventions were neither clearly reported nor controlled. </p> <p>Adverse events were not systematically assessed or reported (or both) by most studies. Therefore, we may have underestimated the prevalence of adverse events. </p> <p>It is possible that we have overestimated risk of bias for studies that failed to report some details of methodology (e.g. randomisation and treatment allocation). </p> <p>The negative results of the nabiximols trials could be due to a relatively high number of patient withdrawals and high mortality rate (<a href="./references#CD014915-bbs2-0028" title="BolandEG , BennettMI , AllgarV , BolandJW . Cannabinoids for adult cancer-related pain: systematic review and meta-analysis. BMJ Supportive and Palliative Care2020;10:14-24. [DOI: 10.1136/bmjspcare-2019-002032]">Boland 2020</a>). The intensity of cancer pain can increase in the end stage of the disease and might have counterbalanced the positive effects of nabiximols. In addition, there is a high degree of variability in pharmacokinetic parameters between participants as well as within participants following single and repeat dosing of oromucosal nabiximols. When nabiximols is administered oromucosally, plasma levels of THC and other CBs are lower compared with the levels achieved following inhalation of CBs at a similar dose (<a href="./references#CD014915-bbs2-0040" title="GW Pharmaceuticals. Sativex oromucosal spray. www.medicines.org.uk/emc/product/602/smp (accessed prior to 3 May 2023).">GW Pharmaceuticals 2020</a>). Insufficient plasma concentrations of nabiximols might be a potential cause of therapeutic failure in some participants of the studies analysed. </p> <p>However, analyses for CbMs as add‐on for opioid refractory cancer pain were dominated (70% or greater weighting) by two large trials that each had about 200 participants in the treatment and placebo groups. The results were negative, and while there was some uncertainty, we have considered that this constitutes no lower than moderate confidence. This is especially the case when the effects of poor quality are almost universally to inflate treatment effect. So the lack of effect in large, reasonably well‐designed studies leads to a conclusion that benefits of CBs tested to date for opioid refractory cancer pain is unlikely. </p> <p>Finally, this systematic review included 1823 participants. To capture rare and potentially severe adverse events a much larger data set is necessary. For example, to capture an adverse event with a frequency of 1 in 100,000 population, 300,000 participants' observations would be required (<a href="./references#CD014915-bbs2-0022" title="AndersohnF , GarbeE . Pharmacoepidemiological research with large health databases. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz2008;51:1135-55. [DOI: 10.1007/s00103-008-0648-9]">Andersohn 2008</a>). We did not look at other data from observational studies for safety evaluations within the scope of our review. </p> </section> <section id="CD014915-sec-0214"> <h3 class="title" id="CD014915-sec-0214">Agreements and disagreements with other studies or reviews</h3> <p>There are numerous reviews available on the efficacy and safety of CbMs and medical cannabis for chronic pain in general. Here, we compare our results only to systematic reviews that included separate analyses for studies on cancer pain. The results and conclusions of our review are not in line with the ones of <a href="./references#CD014915-bbs2-0023" title="AviramJ , Samuelly-LeichtagG . Efficacy of cannabis based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician2017;20:E755-96. [PMID: 28934780]">Aviram 2017</a> and <a href="./references#CD014915-bbs2-0070" title="WangL , HongPJ , MayC , RehmanY , OparinY , HongCJ , et al. Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ2021;374:n1034. [DOI: 10.1136/bmj.n1034]">Wang 2021</a>. <a href="./references#CD014915-bbs2-0023" title="AviramJ , Samuelly-LeichtagG . Efficacy of cannabis based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician2017;20:E755-96. [PMID: 28934780]">Aviram 2017</a> analysed three RCTs with 10 arms that were also included into our analyses and found an SMD for a fixed‐effect model of −0.62 Hedge's g (95% CI −0.80 to −0.44) for mean pain reduction (<a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0009" title="Noyes R Jr, BrunkSF , AveryDA , CanterAC . The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology &amp; Therapy1975;18:84-9. [DOI: 10.1002/cpt197518184]">Noyes 1975a</a>; <a href="./references#CD014915-bbs2-0010" title="Noyes R Jr, BrunkSF , BaramDA , CanterA . Analgesic effect of delta-9-tetrahydrocannabinol. Journal of Clinical Pharmacology1975;15:139-43. [DOI: 10.10.1002/j.1552-4604.1975.tb02348.x]">Noyes 1975b</a>; <a href="./references#CD014915-bbs2-0012" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978a</a>; <a href="./references#CD014915-bbs2-0013" title="StaquetM , GanttC , MachinD . Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clinical Pharmacology &amp; Therapeutics1978;23:397-401. [DOI: 10.1002/cpt1978234397]">Staquet 1978b</a>). The divergent results can be explained as follows: <a href="./references#CD014915-bbs2-0023" title="AviramJ , Samuelly-LeichtagG . Efficacy of cannabis based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician2017;20:E755-96. [PMID: 28934780]">Aviram 2017</a> pooled experimental studies with only one of the studies with negative results with nabiximols in opioid‐refractory cancer pain (<a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>). <a href="./references#CD014915-bbs2-0070" title="WangL , HongPJ , MayC , RehmanY , OparinY , HongCJ , et al. Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ2021;374:n1034. [DOI: 10.1136/bmj.n1034]">Wang 2021</a> concluded that moderate to high certainty evidence showed that, compared with placebo, non‐inhaled medical cannabis or CBs results in a very small to small increase in the proportion of people living with chronic pain. The authors pooled studies with cancer and non‐cancer pain. They included only one study with cancer pain in their analysis of mean pain reduction, which was also included into our review (<a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>). </p> <p>The findings on nabiximols for opioid‐refractory cancer pain are in line with two systematic reviews (<a href="./references#CD014915-bbs2-0028" title="BolandEG , BennettMI , AllgarV , BolandJW . Cannabinoids for adult cancer-related pain: systematic review and meta-analysis. BMJ Supportive and Palliative Care2020;10:14-24. [DOI: 10.1136/bmjspcare-2019-002032]">Boland 2020</a>; <a href="./references#CD014915-bbs2-0046" title="HäuserW , WelschP , KloseP , RadbruchL , FitzcharlesMA . Efficacy, tolerability and safety of cannabis-based medicines for cancer pain. A systematic review with meta-analysis of randomised controlled trials. Schmerz2019;33:424-36. [DOI: 10.1007/s00482-019-037]">Häuser 2019</a>), which included the same studies as we did (<a href="./references#CD014915-bbs2-0002" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017a</a>; <a href="./references#CD014915-bbs2-0003" title="FallonMT , Albert LuxE , McQuadeR , RossettiS , SanchezR , SunW , et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies. British Journal of Pain2017;11:119-33. [DOI: 10.1177/2049463717710042]">Fallon 2017b</a>; <a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>). Nabiximols was not effective in relieving opioid‐refractory cancer and did not reduce maintenance and breakthrough opioid medication. In addition, the use of CbMs was associated with a higher frequency of nervous system and psychiatric disorders compared to placebo. However, serious adverse events did not differ from placebo. These findings were supported by a subgroup analyses of the systematic review of <a href="./references#CD014915-bbs2-0037" title="FisherE , MooreRA , FogartyAE , FinnDP , FinnerupNB , GilronI , et al. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain2021;162(Suppl 1):S45-66. [DOI: 10.1097/j.pain.0000000000001929]">Fisher 2021</a> on participants with cancer pain. It found no superiority of nabiximols over placebo in the two studies that reported the number of participants with pain relief of 30% or greater (<a href="./references#CD014915-bbs2-0006" title="JohnsonJR , Burnell-NugentM , LossignolD , Ganae-MotanED , PottsR , FallonMT . Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. Journal of Pain and Symptom Management2010;39:167-79. [DOI: 10.1016/j.jpainsymman.2009.06.008]">Johnson 2010</a>; <a href="./references#CD014915-bbs2-0011" title="PortenoyRK , Ganae-MotanED , AllendeS , YanagiharaR , ShaiovaL , WeinsteinS , et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. Journal of Pain2012;13:438-49. [DOI: 10.1016/j.jpain.2012.01.003]">Portenoy 2012</a>). In addition, <a href="./references#CD014915-bbs2-0037" title="FisherE , MooreRA , FogartyAE , FinnDP , FinnerupNB , GilronI , et al. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain2021;162(Suppl 1):S45-66. [DOI: 10.1097/j.pain.0000000000001929]">Fisher 2021</a> did not find a benefit of nabiximols compared to placebo for mean pain intensity as reported by four studies (MD on a 0 to 10 scale 0.22, 95% CI −0.49 to 0.06) as we did. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD014915-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/urn:x-wiley:14651858:media:CD014915:CD014915-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD014915-fig-0001" src="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_t/tCD014915-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/full#CD014915-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014915-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/urn:x-wiley:14651858:media:CD014915:CD014915-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD014915-fig-0002" src="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_t/tCD014915-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/full#CD014915-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014915-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/urn:x-wiley:14651858:media:CD014915:CD014915-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD014915-fig-0003" src="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_t/tCD014915-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/full#CD014915-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014915-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/urn:x-wiley:14651858:media:CD014915:CD014915-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain, Outcome 1: Patient Global Impression of Change (PGIC) of much improved or very much improved" data-id="CD014915-fig-0004" src="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_t/tCD014915-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain, Outcome 1: Patient Global Impression of Change (PGIC) of much improved or very much improved </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/references#CD014915-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014915-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/urn:x-wiley:14651858:media:CD014915:CD014915-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain, Outcome 2: Withdrawal due to adverse events" data-id="CD014915-fig-0005" src="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_t/tCD014915-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain, Outcome 2: Withdrawal due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/references#CD014915-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014915-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/urn:x-wiley:14651858:media:CD014915:CD014915-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain, Outcome 3: Pain relief ≥ 30%" data-id="CD014915-fig-0006" src="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_t/tCD014915-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain, Outcome 3: Pain relief ≥ 30% </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/references#CD014915-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014915-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/urn:x-wiley:14651858:media:CD014915:CD014915-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain, Outcome 4: Pain relief ≥ 50%" data-id="CD014915-fig-0007" src="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_t/tCD014915-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain, Outcome 4: Pain relief ≥ 50% </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/references#CD014915-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014915-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/urn:x-wiley:14651858:media:CD014915:CD014915-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain, Outcome 5: Mean pain intensity" data-id="CD014915-fig-0008" src="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_t/tCD014915-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain, Outcome 5: Mean pain intensity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/references#CD014915-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014915-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/urn:x-wiley:14651858:media:CD014915:CD014915-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain, Outcome 6: Sleep problems" data-id="CD014915-fig-0009" src="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_t/tCD014915-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain, Outcome 6: Sleep problems </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/references#CD014915-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014915-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/urn:x-wiley:14651858:media:CD014915:CD014915-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain, Outcome 7: Daily maintenance opioid dosage" data-id="CD014915-fig-0010" src="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_t/tCD014915-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain, Outcome 7: Daily maintenance opioid dosage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/references#CD014915-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014915-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/urn:x-wiley:14651858:media:CD014915:CD014915-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain, Outcome 8: Daily breakthrough opioid dosage" data-id="CD014915-fig-0011" src="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_t/tCD014915-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain, Outcome 8: Daily breakthrough opioid dosage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/references#CD014915-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014915-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/urn:x-wiley:14651858:media:CD014915:CD014915-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain, Outcome 9: All central nervous system adverse events" data-id="CD014915-fig-0012" src="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_t/tCD014915-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain, Outcome 9: All central nervous system adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/references#CD014915-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014915-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/urn:x-wiley:14651858:media:CD014915:CD014915-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain, Outcome 10: All psychiatric adverse events" data-id="CD014915-fig-0013" src="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_t/tCD014915-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain, Outcome 10: All psychiatric adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/references#CD014915-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014915-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/urn:x-wiley:14651858:media:CD014915:CD014915-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain, Outcome 11: Any serious adverse event" data-id="CD014915-fig-0014" src="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_t/tCD014915-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain, Outcome 11: Any serious adverse event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/references#CD014915-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014915-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/urn:x-wiley:14651858:media:CD014915:CD014915-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Experimental studies with synthetic tetrahydrocannabinol (THC) analogue versus placebo for individuals with cancer pain, Outcome 1: Mean pain intensity" data-id="CD014915-fig-0015" src="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_t/tCD014915-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Experimental studies with synthetic tetrahydrocannabinol (THC) analogue versus placebo for individuals with cancer pain, Outcome 1: Mean pain intensity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/references#CD014915-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD014915-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/urn:x-wiley:14651858:media:CD014915:CD014915-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Experimental studies with synthetic tetrahydrocannabinol (THC) analogue versus codeine for individuals with cancer pain, Outcome 1: Mean pain intensity" data-id="CD014915-fig-0016" src="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_t/tCD014915-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Experimental studies with synthetic tetrahydrocannabinol (THC) analogue versus codeine for individuals with cancer pain, Outcome 1: Mean pain intensity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/references#CD014915-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/media/CDSR/CD014915/image_n/nCD014915-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD014915-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Cannabis‐based medicines compared with placebo medication for cancer pain</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Cannabis‐based medicines compared with placebo medication for cancer pain</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with cancer pain </p> <p><b>Settings:</b> outpatient study centres and hospitals in Europe and North America </p> <p><b>Intervention:</b> oromucosal THC with or without CBD </p> <p><b>Comparison:</b> oromucosal placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Observed outcome (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Oromucosal placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Oromucosal THC with or without CBD</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Proportion of participants reporting no worse than mild pain by 14 days after start of treatment</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No data for this outcome were reported.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PGIC of much improved or very much improved</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>230 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>320 per 1000</b><br/>(95% CI 290 to 350 per 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RD 0.06</b> (0.01 to 0.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>996 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTB 16 (95% CI 8 to 100)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>190 per 1000</b><br/>(95% CI 170 to 210 per 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RD 0.04</b> </p> <p>(0.00 to 0.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1332 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNTH 25</p> <p>(95% CI 12 to endless)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean pain intensity</b> (Numeric Rating Scale 0–10) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain intensity at baseline was 5.6 (SD 1.2)<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain intensity in the intervention group was <b>0.19 SDs lower</b> (0.40 lower to 0.02 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD −0.19</b> (−0.40 to 0.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1315 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Daily maintenance opioid dosage</b> (mg morphine equivalent) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean dosage at baseline was 159.7 (SD 121.2) mg/day<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean dosage in the intervention group was <b>0.08 SDs higher</b> (0.10 lower to 0.27 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD 0.08</b> (−0.10 to 0.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>970 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Daily breakthrough opioid dosage</b> (mg morphine equivalent) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean dosage at baseline was 26.4 (SD 40.4) mg/day<sup>b</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean dosage in the intervention group was <b>0.08 SDs lower</b> (0.23 lower to 0.07 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>SMD −0.08</b> (−0.23 to 0.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>957 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participants experiencing any serious adverse event</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>210 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b><br/>(95% CI 220 to 260 per 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RD</b> </p> <p><b>0.02</b> (−0.03 to 0.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1330 (4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CBD:</b> cannabidiol; <b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>PGIC:</b> Patient Global Impression of Change; <b>RD:</b> risk difference; <b>SD:</b> standard deviation; <b>SMD:</b> standardised mean difference; <b>THC:</b> tetrahydrocannabinol. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level due to limitations of study.<br/><sup>b</sup><a href="./references#CD014915-bbs2-0007" title="LichtmanAH , LuxEA , McQuadeR , RossettiS , SanchezR , SunW , et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. Journal of Pain and Symptom Management2018;55(2):179-88.e1. ">Lichtman 2018</a>.<br/><sup>c</sup> Downgraded two levels due to limitations of study design and imprecision of results. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Cannabis‐based medicines compared with placebo medication for cancer pain</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/full#CD014915-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014915-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Patient Global Impression of Change (PGIC) of much improved or very much improved <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.01, 0.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 THC/CBD 1–4 sprays (2.7 mg/2.5 mg to 10.8 mg/10 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.12, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 THC/CBD 6–10 sprays (THC 16.2–27 mg/CBD 15–25 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>805</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.00, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 THC/CBD 11–16 sprays (THC 29.7–43.2 mg/CBD 27.5–40 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.20, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Withdrawal due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.00, 0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 THC/CBD 1–4 sprays (2.7 mg/2.5 mg to 10.8 mg/10 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.21, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 THC/CBD 6–10 sprays (THC 16.2–27 mg/CBD 15–25 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.00, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 THC 6–10 sprays (THC 16.2–27 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.07, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.4 THC/CBD 11–16 sprays (THC 29.7–43.2 mg/CBD 27.5–40 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.09, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Pain relief ≥ 30% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.03, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 THC/CBD 1–4 sprays (2.7 mg/2.5 mg to 10.8 mg/10 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.19, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 THC/CBD 6–10 sprays (THC 16.2–27 mg/CBD 15–25 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.04, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 THC 6–10 sprays (THC 16.2–27 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.18, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 THC/CBD 11–16 sprays (THC 29.7–43.2 mg/CBD 27.5–40 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.20, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Pain relief ≥ 50% <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.02, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 THC/CBD 1–4 sprays (THC/CBD 2.7 mg/2.5 mg to 10.8 mg/10 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.01, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 THC/CBD 6–10 sprays (THC 16.2–27 mg/ CBD 15–25 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.03, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 THC 6–10 sprays (THC 16.2–27 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.13, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.4 THC/CBD 11–16 sprays (THC 29.7–43.2 mg/CBD 27.5–40 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.13, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Mean pain intensity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.40, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 THC/CBD 1–4 sprays (THC/CBD 2.7 mg/2.5 mg to 10.8 mg/10 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.80 [‐1.57, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 THC/CBD 6–10 sprays (THC 16.2–27 mg/CBD 15–25 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐0.42, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 THC 6–10 sprays (THC 16.2–27 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.84, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.4 THC/CBD 11–16 sprays (THC 29.7–43.2 mg/CBD 27.5–40 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.85, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Sleep problems <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.19, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 THC/CBD 1–4 sprays (THC/CBD 2.7 mg/2.5 mg to 10.8 mg/10 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.33 [‐0.74, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 THC/CBD 6–10 sprays (THC 16.2–27 mg/CBD 15–25 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.23, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 THC 6–10 sprays (THC 16.2–27 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.47, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.4 THC/CBD 11–16 sprays (THC/CBD 29.7–43.2 mg/CBD 27.5–40 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.37, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Daily maintenance opioid dosage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.10, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 THC/CBD 6–10 sprays (THC 16.2–27 mg/CBD 15–25 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>883</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.14, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 THC 6–10 sprays (THC 16.2–27 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.05, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Daily breakthrough opioid dosage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>957</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.23, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 THC/CBD 6–10 sprays (THC 16.2–27 mg/CBD 15–25 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>877</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.25, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 THC 6–10 sprays (THC 16.2–27 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [‐0.21, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 All central nervous system adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.05, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 THC/CBD 1–4 sprays (THC/CBD 2.7 mg/2.5 mg to 10.8 mg/10 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.10, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 THC/CBD 6–10 sprays (THC 16.2–27 mg/CBD 15–25 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.03, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 THC 6–10 sprays (THC 16.2–27 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [‐0.07, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.4 THC/CBD 11–16 sprays (THC 29.7–43.2 mg/CBD 27.5–40 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.06, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 All psychiatric adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 THC/CBD 1–4 sprays (THC/CBD 2.7 mg/2.5 mg to 10.8 mg/10 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.12, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.2 THC/CBD 6–10 sprays (THC 16.2–27 mg/CBD 15–25 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.3 THC 6–10 sprays (THC 16.2–27 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.13, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.4 THC/CBD 11–16 sprays (THC 29.7–43.2 mg/CBD 27.5–40 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.04, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Any serious adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.03, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 THC/CBD 1–4 sprays (2.7 mg/2.5 mg to 10.8 mg/10 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.06, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 THC/CBD 6–10 sprays (THC 16.2–27 mg/CBD 15–25 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.06, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.3 THC 6–10 sprays (THC 16.2–27 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [‐0.03, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.4 THC/CBD 11–16 sprays (THC 29.7–43.2 mg/CBD 27.5–40 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.14, 0.23]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Nabiximols (tetrahydrocannabinol (THC) and cannabidiol (CBD)) versus placebo for individuals with opioid‐refractory cancer pain</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/references#CD014915-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014915-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Experimental studies with synthetic tetrahydrocannabinol (THC) analogue versus placebo for individuals with cancer pain</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Mean pain intensity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.98 [‐1.36, ‐0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Synthetic THC analogue 5 mg and 10 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.77 [‐1.19, ‐0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Synthetic THC analogue 15 mg and 20 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.42 [‐2.23, ‐0.62]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Experimental studies with synthetic tetrahydrocannabinol (THC) analogue versus placebo for individuals with cancer pain</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/references#CD014915-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD014915-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Experimental studies with synthetic tetrahydrocannabinol (THC) analogue versus codeine for individuals with cancer pain</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Mean pain intensity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.25, 0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Synthetic THC analogue 4 mg or 10 mg versus codeine 50 mg or 60 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.25, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Synthetic THC analogue 20 mg versus codeine 120 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.57, 0.38]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Experimental studies with synthetic tetrahydrocannabinol (THC) analogue versus codeine for individuals with cancer pain</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD014915.pub2/references#CD014915-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD014915.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD014915-note-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD014915-note-0014">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD014915-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD014915-note-0013">Français</a> </li> <li class="section-language"> <a class="" href="id#CD014915-note-0012">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ja#CD014915-note-0010">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD014915-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD014915-note-0008">Português</a> </li> <li class="section-language"> <a class="" href="th#CD014915-note-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD014915-note-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD014915-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014915\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014915\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014915\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014915\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014915\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014915\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014915\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014915\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014915\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014915\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014915\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014915\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014915\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014915\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014915\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD014915\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD014915\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD014915\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014915.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD014915.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD014915.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD014915.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD014915.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715918840"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014915.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715918844"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD014915.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d92d5cb9e9368',t:'MTc0MDcxNTkxOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 